_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,e1,e2,expdec,rel-type,sent_id,sentence,term1,term2
503669127,7/16/2014 21:19:27,,1324485594,7/16/2014 21:19:09,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],was used in 73 patients with,N/A,41,0,58,11,1,RO-may_treat,908083-FS1,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
503669127,7/16/2014 21:20:08,,1324485922,7/16/2014 21:19:56,instagc,1,28301350,GBR,O4,Torquay,92.23.66.130,[TREATS],[TREATS],used in,N/A,41,0,58,11,1,RO-may_treat,908083-FS1,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
503669127,7/16/2014 21:20:33,,1324486053,7/16/2014 21:20:06,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],was used in,N/A,41,0,58,11,1,RO-may_treat,908083-FS1,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
503669127,7/16/2014 21:23:53,,1324487504,7/16/2014 21:23:40,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],was used in,N/A,41,0,58,11,1,RO-may_treat,908083-FS1,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
503669127,7/16/2014 21:27:43,,1324489202,7/16/2014 21:27:20,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],THALIDOMIDE,asd,41,0,58,11,1,RO-may_treat,908083-FS1,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
503669127,7/16/2014 21:27:59,,1324489298,7/16/2014 21:27:27,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],was used,N/A,41,0,58,11,1,RO-may_treat,908083-FS1,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
503669127,7/16/2014 21:28:32,,1324489512,7/16/2014 21:28:18,instagc,1,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],was used in,N/A,41,0,58,11,1,RO-may_treat,908083-FS1,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
503669127,7/16/2014 21:35:03,,1324492055,7/16/2014 21:34:46,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],used,N/A,41,0,58,11,1,RO-may_treat,908083-FS1,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
503669127,7/16/2014 21:49:13,,1324497662,7/16/2014 21:48:39,elite,1,28276268,USA,TX,Houston,70.140.36.33,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",was used in 73 patients with,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],41,0,58,11,1,RO-may_treat,908083-FS1,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
503669127,7/16/2014 21:57:06,,1324500735,7/16/2014 21:56:45,gifthulk,1,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA,N/A,41,0,58,11,1,RO-may_treat,908083-FS1,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
503669127,7/16/2014 22:08:07,,1324504554,7/16/2014 22:07:34,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],THALIDOMIDE was used in patients with REFRACTORY MYELOMA,n/a,41,0,58,11,1,RO-may_treat,908083-FS1,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
503669127,7/16/2014 22:09:31,,1324504933,7/16/2014 22:08:43,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[TREATS],[TREATS],THALIDOMIDE used in patients with REFRACTORY MYELOMA,N/A,41,0,58,11,1,RO-may_treat,908083-FS1,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
503669127,7/16/2014 22:25:33,,1324511282,7/16/2014 22:25:20,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[TREATS],[TREATS],THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA,N/A,41,0,58,11,1,RO-may_treat,908083-FS1,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
503669127,7/16/2014 22:44:19,,1324519065,7/16/2014 22:43:56,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],was used in patients with,N/A,41,0,58,11,1,RO-may_treat,908083-FS1,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
503669127,7/16/2014 22:53:34,,1324522766,7/16/2014 22:53:02,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],participating in the Japan Myeloma Study Group.,N/A,41,0,58,11,1,RO-may_treat,908083-FS1,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
503669128,7/16/2014 21:22:00,,1324486653,7/16/2014 21:21:38,clixsense,1,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],compared,N/A,141,91,153,106,1,RO-may_treat,907593-FS1,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
503669128,7/16/2014 21:22:12,,1324486727,7/16/2014 21:21:29,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],Administration of,N/A,141,91,153,106,1,RO-may_treat,907593-FS1,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
503669128,7/16/2014 21:29:52,,1324490162,7/16/2014 21:29:39,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],Administration of for,N/A,141,91,153,106,1,RO-may_treat,907593-FS1,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
503669128,7/16/2014 21:31:06,,1324490543,7/16/2014 21:30:37,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],Administration of for,N/A,141,91,153,106,1,RO-may_treat,907593-FS1,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
503669128,7/16/2014 21:31:24,,1324490652,7/16/2014 21:31:01,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],Administration of for,N?A,141,91,153,106,1,RO-may_treat,907593-FS1,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
503669128,7/16/2014 21:33:18,,1324491275,7/16/2014 21:33:02,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CONTRAINDICATES],[CONTRAINDICATES],oral,N/A,141,91,153,106,1,RO-may_treat,907593-FS1,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
503669128,7/16/2014 21:43:31,,1324495415,7/16/2014 21:43:01,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],compared with,N/A,141,91,153,106,1,RO-may_treat,907593-FS1,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
503669128,7/16/2014 21:49:07,,1324497608,7/16/2014 21:48:46,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[NONE],[NONE],N/A,'As compared with' -- differing treatments / conditions,141,91,153,106,1,RO-may_treat,907593-FS1,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
503669128,7/16/2014 22:00:42,,1324501957,7/16/2014 22:00:11,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],as compared with oral danazol for ENDOMETRIOSIS,N/A,141,91,153,106,1,RO-may_treat,907593-FS1,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
503669128,7/16/2014 22:05:26,,1324503771,7/16/2014 22:04:47,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],Administration NASAL NAFARELIN for ENDOMETRIOSIS,n/a,141,91,153,106,1,RO-may_treat,907593-FS1,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
503669128,7/16/2014 22:18:10,,1324508276,7/16/2014 22:17:42,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[TREATS],[TREATS],Administration of for,na,141,91,153,106,1,RO-may_treat,907593-FS1,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
503669128,7/16/2014 22:34:41,,1324515179,7/16/2014 22:33:51,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[CONTRAINDICATES],[CONTRAINDICATES],as compared with,n/a,141,91,153,106,1,RO-may_treat,907593-FS1,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
503669128,7/16/2014 22:55:13,,1324523524,7/16/2014 22:54:44,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared with,N/A,141,91,153,106,1,RO-may_treat,907593-FS1,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
503669128,7/16/2014 23:09:49,,1324528627,7/16/2014 23:09:39,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,list,141,91,153,106,1,RO-may_treat,907593-FS1,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
503669128,7/16/2014 23:14:20,,1324530335,7/16/2014 23:12:34,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[OTHER],[OTHER],compared,comparison,141,91,153,106,1,RO-may_treat,907593-FS1,"1]  Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of NASAL NAFARELIN as compared with oral danazol for ENDOMETRIOSIS",ENDOMETRIOSIS,NASAL NAFARELIN
503669129,7/16/2014 21:20:20,,1324486006,7/16/2014 21:20:09,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[TREATS],[TREATS],treatment,N/A,31,0,49,10,1,RO-may_treat,907950-FS1,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
503669129,7/16/2014 21:21:13,,1324486321,7/16/2014 21:20:52,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treatment,N/A,31,0,49,10,1,RO-may_treat,907950-FS1,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
503669129,7/16/2014 21:22:53,,1324487026,7/16/2014 21:22:43,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],in the treatment of,N/A,31,0,49,10,1,RO-may_treat,907950-FS1,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
503669129,7/16/2014 21:26:16,,1324488579,7/16/2014 21:26:02,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],in the treatment of,N/A,31,0,49,10,1,RO-may_treat,907950-FS1,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
503669129,7/16/2014 21:30:26,,1324490306,7/16/2014 21:30:19,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],in the treatment of,N/A,31,0,49,10,1,RO-may_treat,907950-FS1,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
503669129,7/16/2014 21:31:32,,1324490693,7/16/2014 21:31:07,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],in the treatment of,N/A,31,0,49,10,1,RO-may_treat,907950-FS1,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
503669129,7/16/2014 21:31:48,,1324490797,7/16/2014 21:31:35,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[LOCATION],[LOCATION],AMANTADINE,asd,31,0,49,10,1,RO-may_treat,907950-FS1,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
503669129,7/16/2014 21:49:48,,1324497853,7/16/2014 21:49:39,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[TREATS],[TREATS],AMANTADINE in treatment of PARKINSON'S DISEASE,N/A,31,0,49,10,1,RO-may_treat,907950-FS1,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
503669129,7/16/2014 21:50:43,,1324498227,7/16/2014 21:50:13,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],AMANTADINE treatment PARKINSON'S DISEASE,n/a,31,0,49,10,1,RO-may_treat,907950-FS1,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
503669129,7/16/2014 21:53:49,,1324499548,7/16/2014 21:53:24,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[TREATS],[TREATS],in the treatment of,[TREATS],31,0,49,10,1,RO-may_treat,907950-FS1,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
503669129,7/16/2014 22:00:59,,1324502063,7/16/2014 22:00:47,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],AMANTADINE in the treatment of PARKINSON'S DISEASE,N/A,31,0,49,10,1,RO-may_treat,907950-FS1,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
503669129,7/16/2014 22:04:30,,1324503457,7/16/2014 22:04:11,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],the treatment of,N/A,31,0,49,10,1,RO-may_treat,907950-FS1,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
503669129,7/16/2014 22:18:32,,1324508396,7/16/2014 22:18:13,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[TREATS],[TREATS],AMANTADINE treatment of PARKINSON'S DISEASE,N/A,31,0,49,10,1,RO-may_treat,907950-FS1,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
503669129,7/16/2014 22:44:59,,1324519326,7/16/2014 22:44:36,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],treatment,n/a,31,0,49,10,1,RO-may_treat,907950-FS1,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
503669129,7/16/2014 22:57:05,,1324524262,7/16/2014 22:56:52,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treatment,N/A,31,0,49,10,1,RO-may_treat,907950-FS1,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
503669130,7/16/2014 21:24:05,,1324487625,7/16/2014 21:23:17,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],by damaging,N/A,41,20,55,28,1,RO-disease_has_primary_anatomic_site,902066-FS1,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
503669130,7/16/2014 21:25:42,,1324488342,7/16/2014 21:25:23,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],causes,N/A,41,20,55,28,1,RO-disease_has_primary_anatomic_site,902066-FS1,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
503669130,7/16/2014 21:26:37,,1324488782,7/16/2014 21:26:07,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],causes by damaging,N/A,41,20,55,28,1,RO-disease_has_primary_anatomic_site,902066-FS1,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
503669130,7/16/2014 21:30:19,,1324490271,7/16/2014 21:30:11,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES],[CAUSES],Chemotherapy causes,N/A,41,20,55,28,1,RO-disease_has_primary_anatomic_site,902066-FS1,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
503669130,7/16/2014 21:31:32,,1324490698,7/16/2014 21:31:04,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],damaging,N/A,41,20,55,28,1,RO-disease_has_primary_anatomic_site,902066-FS1,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
503669130,7/16/2014 21:37:21,,1324492975,7/16/2014 21:36:52,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],damaging,N/A,41,20,55,28,1,RO-disease_has_primary_anatomic_site,902066-FS1,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
503669130,7/16/2014 21:39:27,,1324493752,7/16/2014 21:39:09,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[CAUSES],[CAUSES],causes ALOPECIA by damaging HAIR STEM CELLS,N/A,41,20,55,28,1,RO-disease_has_primary_anatomic_site,902066-FS1,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
503669130,7/16/2014 21:40:26,,1324494182,7/16/2014 21:40:06,clixsense,1.0,15189335,GBR,H9,London,188.29.165.50,[CAUSES],[CAUSES],causes by damaging,Na,41,20,55,28,1,RO-disease_has_primary_anatomic_site,902066-FS1,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
503669130,7/16/2014 21:46:36,,1324496718,7/16/2014 21:46:07,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",by damaging,[CAUSES] [SYMPTOM],41,20,55,28,1,RO-disease_has_primary_anatomic_site,902066-FS1,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
503669130,7/16/2014 21:55:55,,1324500326,7/16/2014 21:55:19,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],causes by damaging,N/A,41,20,55,28,1,RO-disease_has_primary_anatomic_site,902066-FS1,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
503669130,7/16/2014 22:06:17,,1324504044,7/16/2014 22:05:19,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[SYMPTOM] [LOCATION],"[LOCATION]
[SYMPTOM]",by damaging HAIR STEM CELLS,na,41,20,55,28,1,RO-disease_has_primary_anatomic_site,902066-FS1,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
503669130,7/16/2014 22:22:46,,1324510294,7/16/2014 22:22:27,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],ALOPECIA by damaging HAIR STEM CELLS,N/A,41,20,55,28,1,RO-disease_has_primary_anatomic_site,902066-FS1,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
503669130,7/16/2014 22:32:37,,1324514285,7/16/2014 22:30:20,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],damaging,n/a,41,20,55,28,1,RO-disease_has_primary_anatomic_site,902066-FS1,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
503669130,7/16/2014 22:34:54,,1324515283,7/16/2014 22:32:39,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[MANIFESTATION],[MANIFESTATION],Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and making hair brittle,N/A,41,20,55,28,1,RO-disease_has_primary_anatomic_site,902066-FS1,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
503669130,7/16/2014 23:02:36,,1324526056,7/16/2014 23:01:04,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES],[CAUSES],Chemotherapy causes,N/A,41,20,55,28,1,RO-disease_has_primary_anatomic_site,902066-FS1,Chemotherapy causes ALOPECIA by damaging HAIR STEM CELLS and hair follicles making the hair brittle and causing scalp hair to break off or fall out.,HAIR STEM CELLS,ALOPECIA
503669131,7/16/2014 21:21:24,,1324486358,7/16/2014 21:20:15,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],report,N/A,98,131,112,155,1,RO-disease_may_have_finding,902861-FS1,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
503669131,7/16/2014 21:21:41,,1324486463,7/16/2014 21:21:08,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[SIDE_EFFECT],[SIDE_EFFECT],in the course of,N/A,98,131,112,155,1,RO-disease_may_have_finding,902861-FS1,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
503669131,7/16/2014 21:22:42,,1324486946,7/16/2014 21:22:23,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],in the course,N/A,98,131,112,155,1,RO-disease_may_have_finding,902861-FS1,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
503669131,7/16/2014 21:25:22,,1324488207,7/16/2014 21:25:01,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treatment,N/A,98,131,112,155,1,RO-disease_may_have_finding,902861-FS1,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
503669131,7/16/2014 21:25:59,,1324488474,7/16/2014 21:25:31,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[SYMPTOM],[SYMPTOM],in the course,N/A,98,131,112,155,1,RO-disease_may_have_finding,902861-FS1,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
503669131,7/16/2014 21:28:01,,1324489313,7/16/2014 21:27:45,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],in the course of,N/A,98,131,112,155,1,RO-disease_may_have_finding,902861-FS1,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
503669131,7/16/2014 21:31:16,,1324490605,7/16/2014 21:31:03,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[MANIFESTATION],[MANIFESTATION],MONONUCLEOSIS,asd,98,131,112,155,1,RO-disease_may_have_finding,902861-FS1,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
503669131,7/16/2014 21:40:56,,1324494380,7/16/2014 21:40:27,clixsense,1.0,15189335,GBR,H9,London,188.29.165.50,[TREATS],[TREATS],conservative surgical treatment,Na,98,131,112,155,1,RO-disease_may_have_finding,902861-FS1,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
503669131,7/16/2014 21:51:00,,1324498333,7/16/2014 21:50:27,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[TREATS] [CAUSES],"[TREATS]
[CAUSES]",treatment of in the course of,[TREATS] [CAUSES],98,131,112,155,1,RO-disease_may_have_finding,902861-FS1,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
503669131,7/16/2014 22:00:45,,1324501991,7/16/2014 21:59:47,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SPLENIC RUPTURE course of INFECTIOUS MONONUCLEOSIS,n/a,98,131,112,155,1,RO-disease_may_have_finding,902861-FS1,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
503669131,7/16/2014 22:23:23,,1324510485,7/16/2014 22:23:03,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,N/A,98,131,112,155,1,RO-disease_may_have_finding,902861-FS1,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
503669131,7/16/2014 22:38:52,,1324517134,7/16/2014 22:38:29,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],surgical treatment of in the course,n/a,98,131,112,155,1,RO-disease_may_have_finding,902861-FS1,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
503669131,7/16/2014 23:07:45,,1324527891,7/16/2014 23:07:24,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],surgical treatment,N/A,98,131,112,155,1,RO-disease_may_have_finding,902861-FS1,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
503669131,7/16/2014 23:10:18,,1324528786,7/16/2014 23:10:03,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[CAUSES],[CAUSES],course of,N/A,98,131,112,155,1,RO-disease_may_have_finding,902861-FS1,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
503669131,7/16/2014 23:22:19,,1324534174,7/16/2014 23:21:50,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM],[SYMPTOM],SPLENIC RUPTURE the course of INFECTIOUS MONONUCLEOSIS,N/A,98,131,112,155,1,RO-disease_may_have_finding,902861-FS1,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
503669132,7/16/2014 21:19:39,,1324485687,7/16/2014 21:19:06,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],severity of the,N/A,89,52,96,68,-1,RO-has_definitional_manifestation,904841-FS1,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
503669132,7/16/2014 21:21:37,,1324486439,7/16/2014 21:21:14,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],the,N/A,89,52,96,68,-1,RO-has_definitional_manifestation,904841-FS1,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
503669132,7/16/2014 21:23:59,,1324487567,7/16/2014 21:23:30,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[CAUSES],[CAUSES],with severity,N/A,89,52,96,68,-1,RO-has_definitional_manifestation,904841-FS1,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
503669132,7/16/2014 21:25:28,,1324488228,7/16/2014 21:24:23,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],During therapy of,N/A,89,52,96,68,-1,RO-has_definitional_manifestation,904841-FS1,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
503669132,7/16/2014 21:30:09,,1324490245,7/16/2014 21:29:53,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CAUSES],[CAUSES],severity,N/A,89,52,96,68,-1,RO-has_definitional_manifestation,904841-FS1,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
503669132,7/16/2014 21:33:50,,1324491621,7/16/2014 21:33:31,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],severity of the,N/A,89,52,96,68,-1,RO-has_definitional_manifestation,904841-FS1,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
503669132,7/16/2014 21:36:03,,1324492527,7/16/2014 21:35:51,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SYMPTOM],[SYMPTOM],patients 57,asd,89,52,96,68,-1,RO-has_definitional_manifestation,904841-FS1,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
503669132,7/16/2014 21:49:25,,1324497725,7/16/2014 21:49:08,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[CAUSES],[CAUSES],During therapy PARTIAL EPILEPSY severity of SEIZURES,N/A,89,52,96,68,-1,RO-has_definitional_manifestation,904841-FS1,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
503669132,7/16/2014 21:59:30,,1324501574,7/16/2014 21:58:51,clixsense,1,19500241,USA,NC,Greensboro,174.98.255.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as,N/A,89,52,96,68,-1,RO-has_definitional_manifestation,904841-FS1,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
503669132,7/16/2014 22:10:20,,1324505206,7/16/2014 22:09:53,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[SYMPTOM],[SYMPTOM],severity of,Na,89,52,96,68,-1,RO-has_definitional_manifestation,904841-FS1,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
503669132,7/16/2014 22:14:16,,1324506714,7/16/2014 22:13:46,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[SYMPTOM],[SYMPTOM],severity of the,na,89,52,96,68,-1,RO-has_definitional_manifestation,904841-FS1,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
503669132,7/16/2014 22:44:34,,1324519147,7/16/2014 22:43:58,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[SYMPTOM],[SYMPTOM],the severity,n/a,89,52,96,68,-1,RO-has_definitional_manifestation,904841-FS1,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
503669132,7/16/2014 22:50:31,,1324521408,7/16/2014 22:50:05,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,89,52,96,68,-1,RO-has_definitional_manifestation,904841-FS1,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
503669132,7/16/2014 23:07:23,,1324527776,7/16/2014 23:06:54,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],patients were evaluated.,N/A,89,52,96,68,-1,RO-has_definitional_manifestation,904841-FS1,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
503669132,7/16/2014 23:14:57,,1324530560,7/16/2014 23:14:42,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[SYMPTOM],[SYMPTOM],severity of,N/A,89,52,96,68,-1,RO-has_definitional_manifestation,904841-FS1,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
503669133,7/16/2014 21:23:37,,1324487353,7/16/2014 21:22:54,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],no reported increase in,N/A,124,85,131,106,-1,RO-has_definitional_manifestation,904689-FS1,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
503669133,7/16/2014 21:28:45,,1324489660,7/16/2014 21:28:11,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],and no new onset,N/A,124,85,131,106,-1,RO-has_definitional_manifestation,904689-FS1,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
503669133,7/16/2014 21:30:09,,1324490252,7/16/2014 21:28:56,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],PRE EXISTING EPILEPSY SEIZURES.,N/A,124,85,131,106,-1,RO-has_definitional_manifestation,904689-FS1,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
503669133,7/16/2014 21:30:44,,1324490428,7/16/2014 21:30:33,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],seizures starting,asdz,124,85,131,106,-1,RO-has_definitional_manifestation,904689-FS1,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
503669133,7/16/2014 21:33:01,,1324491223,7/16/2014 21:32:47,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SYMPTOM],[SYMPTOM],onset,N/A,124,85,131,106,-1,RO-has_definitional_manifestation,904689-FS1,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
503669133,7/16/2014 21:33:30,,1324491431,7/16/2014 21:33:09,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],no new,N/A,124,85,131,106,-1,RO-has_definitional_manifestation,904689-FS1,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
503669133,7/16/2014 21:41:05,,1324494446,7/16/2014 21:40:33,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CONTRAINDICATES],[CONTRAINDICATES],was reported in,N/A,124,85,131,106,-1,RO-has_definitional_manifestation,904689-FS1,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
503669133,7/16/2014 21:48:21,,1324497316,7/16/2014 21:47:58,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[OTHER],[OTHER],PRE EXISTING EPILEPSY and no new onset SEIZURES.,The relation is not clear in this extract,124,85,131,106,-1,RO-has_definitional_manifestation,904689-FS1,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
503669133,7/16/2014 22:02:34,,1324502694,7/16/2014 22:02:05,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,124,85,131,106,-1,RO-has_definitional_manifestation,904689-FS1,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
503669133,7/16/2014 22:03:57,,1324503278,7/16/2014 22:03:26,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[MANIFESTATION],[MANIFESTATION],no reported increase in seizures in children with PRE EXISTING EPILEPSY,N/A,124,85,131,106,-1,RO-has_definitional_manifestation,904689-FS1,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
503669133,7/16/2014 22:07:46,,1324504459,7/16/2014 22:06:53,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[SYMPTOM],[SYMPTOM],seizures with,na,124,85,131,106,-1,RO-has_definitional_manifestation,904689-FS1,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
503669133,7/16/2014 22:14:34,,1324506819,7/16/2014 22:14:21,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],PRE EXISTING EPILEPSY and SEIZURES.,N/A,124,85,131,106,-1,RO-has_definitional_manifestation,904689-FS1,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
503669133,7/16/2014 22:45:40,,1324519585,7/16/2014 22:45:10,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],and no new onset,N/A,124,85,131,106,-1,RO-has_definitional_manifestation,904689-FS1,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
503669133,7/16/2014 22:48:04,,1324520598,7/16/2014 22:47:49,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,124,85,131,106,-1,RO-has_definitional_manifestation,904689-FS1,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
503669133,7/16/2014 22:48:11,,1324520646,7/16/2014 22:47:17,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],and no new onset,n/a,124,85,131,106,-1,RO-has_definitional_manifestation,904689-FS1,There was no reported increase in seizures after starting melatonin in children with PRE EXISTING EPILEPSY and no new onset SEIZURES.,SEIZURES,PRE EXISTING EPILEPSY
503669134,7/16/2014 21:23:29,,1324487316,7/16/2014 21:23:09,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[CAUSES],[CAUSES],after,N/A,99,45,112,52,1,RO-has_causative_agent,903998-FS1,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
503669134,7/16/2014 21:26:32,,1324488715,7/16/2014 21:25:58,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],after,N/A,99,45,112,52,1,RO-has_causative_agent,903998-FS1,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
503669134,7/16/2014 21:26:57,,1324488914,7/16/2014 21:26:40,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SIDE_EFFECT],[SIDE_EFFECT],VIREMIA,asd,99,45,112,52,1,RO-has_causative_agent,903998-FS1,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
503669134,7/16/2014 21:27:54,,1324489268,7/16/2014 21:27:30,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],and development after,N/A,99,45,112,52,1,RO-has_causative_agent,903998-FS1,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
503669134,7/16/2014 21:29:11,,1324489861,7/16/2014 21:28:57,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],after,N/A,99,45,112,52,1,RO-has_causative_agent,903998-FS1,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
503669134,7/16/2014 21:45:27,,1324496237,7/16/2014 21:44:50,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[ASSOCIATED_WITH],[ASSOCIATED_WITH],related disease after,[ASSOCIATED_WITH],99,45,112,52,1,RO-has_causative_agent,903998-FS1,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
503669134,7/16/2014 21:47:57,,1324497201,7/16/2014 21:47:37,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[CAUSES],[CAUSES],VIREMIA after VIRUS EXPOSURE,N/A,99,45,112,52,1,RO-has_causative_agent,903998-FS1,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
503669134,7/16/2014 21:56:44,,1324500609,7/16/2014 21:54:12,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[CAUSES],[CAUSES],VIREMIA disease after VIRUS EXPOSURE,N/A,99,45,112,52,1,RO-has_causative_agent,903998-FS1,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
503669134,7/16/2014 22:03:37,,1324503096,7/16/2014 22:03:05,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[CAUSES] [OTHER],"[CAUSES]
[OTHER]",development of related disease after,N/A,99,45,112,52,1,RO-has_causative_agent,903998-FS1,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
503669134,7/16/2014 22:04:45,,1324503519,7/16/2014 22:04:06,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[CAUSES],[CAUSES],VIREMIA after VIRUS EXPOSURE,n/a,99,45,112,52,1,RO-has_causative_agent,903998-FS1,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
503669134,7/16/2014 22:14:58,,1324506978,7/16/2014 22:14:21,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[CAUSES],[CAUSES],VIRUS EXPOSURE,na,99,45,112,52,1,RO-has_causative_agent,903998-FS1,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
503669134,7/16/2014 22:22:26,,1324510086,7/16/2014 22:21:43,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[MANIFESTATION],[MANIFESTATION],VIREMIA and development of FeLV related disease after VIRUS EXPOSURE,N/A,99,45,112,52,1,RO-has_causative_agent,903998-FS1,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
503669134,7/16/2014 22:40:39,,1324517877,7/16/2014 22:39:08,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],prevent,n/a,99,45,112,52,1,RO-has_causative_agent,903998-FS1,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
503669134,7/16/2014 22:57:19,,1324524344,7/16/2014 22:56:12,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[PREVENTS],[PREVENTS],vaccines prevent persistent VIREMIA,N/A,99,45,112,52,1,RO-has_causative_agent,903998-FS1,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
503669134,7/16/2014 23:12:44,,1324529754,7/16/2014 23:12:33,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,list,99,45,112,52,1,RO-has_causative_agent,903998-FS1,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
503669135,7/16/2014 21:24:18,,1324487705,7/16/2014 21:23:54,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],administration of,N/A,106,84,121,96,1,RO-may_diagnose,906704-FS1,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
503669135,7/16/2014 21:25:44,,1324488349,7/16/2014 21:25:33,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],administration of,N?A,106,84,121,96,1,RO-may_diagnose,906704-FS1,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
503669135,7/16/2014 21:29:22,,1324489969,7/16/2014 21:28:56,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[CAUSES],[CAUSES],administration suggests,N/A,106,84,121,96,1,RO-may_diagnose,906704-FS1,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
503669135,7/16/2014 21:29:55,,1324490183,7/16/2014 21:29:41,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],suggests,N/A,106,84,121,96,1,RO-may_diagnose,906704-FS1,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
503669135,7/16/2014 21:31:29,,1324490686,7/16/2014 21:31:07,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],administration of suggests,N/A,106,84,121,96,1,RO-may_diagnose,906704-FS1,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
503669135,7/16/2014 21:34:38,,1324491935,7/16/2014 21:33:49,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],responses frequent.,asd,106,84,121,96,1,RO-may_diagnose,906704-FS1,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
503669135,7/16/2014 21:37:55,,1324493147,7/16/2014 21:37:22,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],suggests,N/A,106,84,121,96,1,RO-may_diagnose,906704-FS1,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
503669135,7/16/2014 21:51:37,,1324498595,7/16/2014 21:50:44,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reduction BP following administration PHENTOLAMINE PHEOCHROMOCYTOMA;,n/a,106,84,121,96,1,RO-may_diagnose,906704-FS1,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
503669135,7/16/2014 21:53:54,,1324499587,7/16/2014 21:53:25,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],a Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;,N/A,106,84,121,96,1,RO-may_diagnose,906704-FS1,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
503669135,7/16/2014 21:59:48,,1324501676,7/16/2014 21:59:14,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",suggests,Na,106,84,121,96,1,RO-may_diagnose,906704-FS1,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
503669135,7/16/2014 22:19:26,,1324508843,7/16/2014 22:18:15,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[CAUSES],[CAUSES],following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;,na,106,84,121,96,1,RO-may_diagnose,906704-FS1,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
503669135,7/16/2014 22:25:19,,1324511171,7/16/2014 22:25:06,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[TREATS],[TREATS],administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;,N/A,106,84,121,96,1,RO-may_diagnose,906704-FS1,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
503669135,7/16/2014 22:47:14,,1324520319,7/16/2014 22:46:39,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[SYMPTOM],[SYMPTOM],suggests,n/a,106,84,121,96,1,RO-may_diagnose,906704-FS1,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
503669135,7/16/2014 22:55:43,,1324523697,7/16/2014 22:55:15,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],marked reduction,N/A,106,84,121,96,1,RO-may_diagnose,906704-FS1,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
503669135,7/16/2014 23:14:25,,1324530388,7/16/2014 23:14:11,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],suggests,N/A,106,84,121,96,1,RO-may_diagnose,906704-FS1,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
503669136,7/16/2014 21:19:33,,1324485643,7/16/2014 21:19:22,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,44,18,61,39,-1,RO-has_manifestation,906308-FS1,Two patients with KEARNS SAYRE SYNDROME and HYPOPARATHYROIDISM were treated with alfacalcidol (1a OH D3) and total serum calcium concentration remained within normal range for a long period.,HYPOPARATHYROIDISM,KEARNS SAYRE SYNDROME
503669136,7/16/2014 21:25:49,,1324488412,7/16/2014 21:25:05,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Two patients with and were treated with alfacalcidol,N/A,44,18,61,39,-1,RO-has_manifestation,906308-FS1,Two patients with KEARNS SAYRE SYNDROME and HYPOPARATHYROIDISM were treated with alfacalcidol (1a OH D3) and total serum calcium concentration remained within normal range for a long period.,HYPOPARATHYROIDISM,KEARNS SAYRE SYNDROME
503669136,7/16/2014 21:26:27,,1324488676,7/16/2014 21:26:09,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treated,N/A,44,18,61,39,-1,RO-has_manifestation,906308-FS1,Two patients with KEARNS SAYRE SYNDROME and HYPOPARATHYROIDISM were treated with alfacalcidol (1a OH D3) and total serum calcium concentration remained within normal range for a long period.,HYPOPARATHYROIDISM,KEARNS SAYRE SYNDROME
503669136,7/16/2014 21:28:56,,1324489749,7/16/2014 21:28:34,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with and were treated with,N/A,44,18,61,39,-1,RO-has_manifestation,906308-FS1,Two patients with KEARNS SAYRE SYNDROME and HYPOPARATHYROIDISM were treated with alfacalcidol (1a OH D3) and total serum calcium concentration remained within normal range for a long period.,HYPOPARATHYROIDISM,KEARNS SAYRE SYNDROME
503669136,7/16/2014 21:31:03,,1324490528,7/16/2014 21:30:42,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,44,18,61,39,-1,RO-has_manifestation,906308-FS1,Two patients with KEARNS SAYRE SYNDROME and HYPOPARATHYROIDISM were treated with alfacalcidol (1a OH D3) and total serum calcium concentration remained within normal range for a long period.,HYPOPARATHYROIDISM,KEARNS SAYRE SYNDROME
503669136,7/16/2014 21:32:41,,1324491144,7/16/2014 21:31:33,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]",were treated with,N/A,44,18,61,39,-1,RO-has_manifestation,906308-FS1,Two patients with KEARNS SAYRE SYNDROME and HYPOPARATHYROIDISM were treated with alfacalcidol (1a OH D3) and total serum calcium concentration remained within normal range for a long period.,HYPOPARATHYROIDISM,KEARNS SAYRE SYNDROME
503669136,7/16/2014 21:33:59,,1324491674,7/16/2014 21:33:35,clixsense,1.0,15189335,GBR,H9,London,188.29.164.50,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with and,Na,44,18,61,39,-1,RO-has_manifestation,906308-FS1,Two patients with KEARNS SAYRE SYNDROME and HYPOPARATHYROIDISM were treated with alfacalcidol (1a OH D3) and total serum calcium concentration remained within normal range for a long period.,HYPOPARATHYROIDISM,KEARNS SAYRE SYNDROME
503669136,7/16/2014 21:57:33,,1324500880,7/16/2014 21:56:58,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],KEARNS SAYRE SYNDROME and HYPOPARATHYROIDISM,n/a,44,18,61,39,-1,RO-has_manifestation,906308-FS1,Two patients with KEARNS SAYRE SYNDROME and HYPOPARATHYROIDISM were treated with alfacalcidol (1a OH D3) and total serum calcium concentration remained within normal range for a long period.,HYPOPARATHYROIDISM,KEARNS SAYRE SYNDROME
503669136,7/16/2014 21:58:20,,1324501174,7/16/2014 21:58:06,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Two patients with KEARNS SAYRE SYNDROME and HYPOPARATHYROIDISM,N/A,44,18,61,39,-1,RO-has_manifestation,906308-FS1,Two patients with KEARNS SAYRE SYNDROME and HYPOPARATHYROIDISM were treated with alfacalcidol (1a OH D3) and total serum calcium concentration remained within normal range for a long period.,HYPOPARATHYROIDISM,KEARNS SAYRE SYNDROME
503669136,7/16/2014 22:26:51,,1324511897,7/16/2014 22:26:17,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[ASSOCIATED_WITH],[ASSOCIATED_WITH],KEARNS SAYRE SYNDROME and HYPOPARATHYROIDISM were treated with alfacalcidol,N/A,44,18,61,39,-1,RO-has_manifestation,906308-FS1,Two patients with KEARNS SAYRE SYNDROME and HYPOPARATHYROIDISM were treated with alfacalcidol (1a OH D3) and total serum calcium concentration remained within normal range for a long period.,HYPOPARATHYROIDISM,KEARNS SAYRE SYNDROME
503669136,7/16/2014 22:47:26,,1324520405,7/16/2014 22:47:06,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],and,N/A,44,18,61,39,-1,RO-has_manifestation,906308-FS1,Two patients with KEARNS SAYRE SYNDROME and HYPOPARATHYROIDISM were treated with alfacalcidol (1a OH D3) and total serum calcium concentration remained within normal range for a long period.,HYPOPARATHYROIDISM,KEARNS SAYRE SYNDROME
503669136,7/16/2014 22:50:00,,1324521217,7/16/2014 22:49:45,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,44,18,61,39,-1,RO-has_manifestation,906308-FS1,Two patients with KEARNS SAYRE SYNDROME and HYPOPARATHYROIDISM were treated with alfacalcidol (1a OH D3) and total serum calcium concentration remained within normal range for a long period.,HYPOPARATHYROIDISM,KEARNS SAYRE SYNDROME
503669136,7/16/2014 23:04:39,,1324526838,7/16/2014 23:04:19,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],were treated with alfacalcidol,N/A,44,18,61,39,-1,RO-has_manifestation,906308-FS1,Two patients with KEARNS SAYRE SYNDROME and HYPOPARATHYROIDISM were treated with alfacalcidol (1a OH D3) and total serum calcium concentration remained within normal range for a long period.,HYPOPARATHYROIDISM,KEARNS SAYRE SYNDROME
503669136,7/16/2014 23:13:49,,1324530177,7/16/2014 23:13:37,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,44,18,61,39,-1,RO-has_manifestation,906308-FS1,Two patients with KEARNS SAYRE SYNDROME and HYPOPARATHYROIDISM were treated with alfacalcidol (1a OH D3) and total serum calcium concentration remained within normal range for a long period.,HYPOPARATHYROIDISM,KEARNS SAYRE SYNDROME
503669136,7/16/2014 23:16:52,,1324531346,7/16/2014 23:16:21,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated terms,44,18,61,39,-1,RO-has_manifestation,906308-FS1,Two patients with KEARNS SAYRE SYNDROME and HYPOPARATHYROIDISM were treated with alfacalcidol (1a OH D3) and total serum calcium concentration remained within normal range for a long period.,HYPOPARATHYROIDISM,KEARNS SAYRE SYNDROME
503669137,7/16/2014 21:19:54,,1324485829,7/16/2014 21:19:38,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared,N/A,129,39,140,62,1,RO-disease_has_primary_anatomic_site,902348-FS1,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
503669137,7/16/2014 21:23:15,,1324487168,7/16/2014 21:22:29,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],have been compared with skin biopsies developing,N/A,129,39,140,62,1,RO-disease_has_primary_anatomic_site,902348-FS1,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
503669137,7/16/2014 21:31:22,,1324490638,7/16/2014 21:29:46,clixsense,1.0,15189335,GBR,H9,London,188.29.164.50,[CAUSES],[CAUSES],been compared,Na,129,39,140,62,1,RO-disease_has_primary_anatomic_site,902348-FS1,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
503669137,7/16/2014 21:33:55,,1324491645,7/16/2014 21:33:36,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SIDE_EFFECT],[SIDE_EFFECT],developing,N/A,129,39,140,62,1,RO-disease_has_primary_anatomic_site,902348-FS1,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
503669137,7/16/2014 21:35:47,,1324492414,7/16/2014 21:35:35,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SYMPTOM],[SYMPTOM],DRUG INDUCED DERMATITIS,asd,129,39,140,62,1,RO-disease_has_primary_anatomic_site,902348-FS1,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
503669137,7/16/2014 21:42:13,,1324494850,7/16/2014 21:41:32,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,different conditions,129,39,140,62,1,RO-disease_has_primary_anatomic_site,902348-FS1,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
503669137,7/16/2014 21:46:05,,1324496517,7/16/2014 21:45:30,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],have been compared with,[DIAGNOSE_BY_TEST_OR_DRUG],129,39,140,62,1,RO-disease_has_primary_anatomic_site,902348-FS1,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
503669137,7/16/2014 21:57:41,,1324500927,7/16/2014 21:57:02,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],have been compared with skin biopsies developing,N/A,129,39,140,62,1,RO-disease_has_primary_anatomic_site,902348-FS1,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
503669137,7/16/2014 21:58:54,,1324501368,7/16/2014 21:58:21,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Skin biopsies from patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from patients developing SKIN LESIONS,N/A,129,39,140,62,1,RO-disease_has_primary_anatomic_site,902348-FS1,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
503669137,7/16/2014 22:02:31,,1324502679,7/16/2014 22:01:25,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[LOCATION] [OTHER],"[LOCATION]
[OTHER]",DRUG INDUCED DERMATITIS have been compared developing SKIN LESIONS,In comparison,129,39,140,62,1,RO-disease_has_primary_anatomic_site,902348-FS1,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
503669137,7/16/2014 22:13:03,,1324506196,7/16/2014 22:10:57,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[SYMPTOM],[SYMPTOM],DRUG INDUCED DERMATITIS skin biopsies from patients developing SKIN LESIONS,N/A,129,39,140,62,1,RO-disease_has_primary_anatomic_site,902348-FS1,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
503669137,7/16/2014 22:22:05,,1324509957,7/16/2014 22:21:05,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[OTHER],[OTHER],compared,compared,129,39,140,62,1,RO-disease_has_primary_anatomic_site,902348-FS1,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
503669137,7/16/2014 22:57:45,,1324524497,7/16/2014 22:57:21,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],have been compared with,N/A,129,39,140,62,1,RO-disease_has_primary_anatomic_site,902348-FS1,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
503669137,7/16/2014 23:08:55,,1324528288,7/16/2014 23:08:41,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[CAUSES],[CAUSES],developing,N/A,129,39,140,62,1,RO-disease_has_primary_anatomic_site,902348-FS1,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
503669137,7/16/2014 23:16:24,,1324531151,7/16/2014 23:14:22,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[OTHER],[OTHER],compared,comparison,129,39,140,62,1,RO-disease_has_primary_anatomic_site,902348-FS1,Skin biopsies from eight patients with DRUG INDUCED DERMATITIS have been compared with skin biopsies from 16 patients developing SKIN LESIONS (acute graft versus host reaction and/or drug induced reaction) after bone marrow transplantation.,SKIN LESIONS,DRUG INDUCED DERMATITIS
503669138,7/16/2014 21:24:00,,1324487581,7/16/2014 21:23:33,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],reduced,N/A,82,59,95,77,-1,RO-has_causative_agent,903515-FS1,Soaking dentures in denture cleanser reduced the degree of DENTURE STOMATITIS and DENTURE PLAQUE.,DENTURE PLAQUE,DENTURE STOMATITIS
503669138,7/16/2014 21:26:16,,1324488584,7/16/2014 21:25:51,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[ASSOCIATED_WITH],[ASSOCIATED_WITH],reduced the degree of and,N/A,82,59,95,77,-1,RO-has_causative_agent,903515-FS1,Soaking dentures in denture cleanser reduced the degree of DENTURE STOMATITIS and DENTURE PLAQUE.,DENTURE PLAQUE,DENTURE STOMATITIS
503669138,7/16/2014 21:26:35,,1324488739,7/16/2014 21:26:21,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,82,59,95,77,-1,RO-has_causative_agent,903515-FS1,Soaking dentures in denture cleanser reduced the degree of DENTURE STOMATITIS and DENTURE PLAQUE.,DENTURE PLAQUE,DENTURE STOMATITIS
503669138,7/16/2014 21:26:57,,1324488917,7/16/2014 21:25:42,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,82,59,95,77,-1,RO-has_causative_agent,903515-FS1,Soaking dentures in denture cleanser reduced the degree of DENTURE STOMATITIS and DENTURE PLAQUE.,DENTURE PLAQUE,DENTURE STOMATITIS
503669138,7/16/2014 21:29:11,,1324489867,7/16/2014 21:27:47,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[MANIFESTATION],[MANIFESTATION],reduced,asd,82,59,95,77,-1,RO-has_causative_agent,903515-FS1,Soaking dentures in denture cleanser reduced the degree of DENTURE STOMATITIS and DENTURE PLAQUE.,DENTURE PLAQUE,DENTURE STOMATITIS
503669138,7/16/2014 21:29:40,,1324490088,7/16/2014 21:29:02,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[PREVENTS],[PREVENTS],reduced,N/A,82,59,95,77,-1,RO-has_causative_agent,903515-FS1,Soaking dentures in denture cleanser reduced the degree of DENTURE STOMATITIS and DENTURE PLAQUE.,DENTURE PLAQUE,DENTURE STOMATITIS
503669138,7/16/2014 21:31:00,,1324490516,7/16/2014 21:30:44,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N?A,82,59,95,77,-1,RO-has_causative_agent,903515-FS1,Soaking dentures in denture cleanser reduced the degree of DENTURE STOMATITIS and DENTURE PLAQUE.,DENTURE PLAQUE,DENTURE STOMATITIS
503669138,7/16/2014 21:44:21,,1324495720,7/16/2014 21:44:05,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Soaking dentures reduced DENTURE STOMATITIS and DENTURE PLAQUE.,N/A,82,59,95,77,-1,RO-has_causative_agent,903515-FS1,Soaking dentures in denture cleanser reduced the degree of DENTURE STOMATITIS and DENTURE PLAQUE.,DENTURE PLAQUE,DENTURE STOMATITIS
503669138,7/16/2014 21:50:12,,1324498032,7/16/2014 21:49:06,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DENTURE STOMATITIS and DENTURE PLAQUE.,n/a,82,59,95,77,-1,RO-has_causative_agent,903515-FS1,Soaking dentures in denture cleanser reduced the degree of DENTURE STOMATITIS and DENTURE PLAQUE.,DENTURE PLAQUE,DENTURE STOMATITIS
503669138,7/16/2014 22:05:14,,1324503675,7/16/2014 22:04:29,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[NONE],[NONE],na,separate,82,59,95,77,-1,RO-has_causative_agent,903515-FS1,Soaking dentures in denture cleanser reduced the degree of DENTURE STOMATITIS and DENTURE PLAQUE.,DENTURE PLAQUE,DENTURE STOMATITIS
503669138,7/16/2014 22:27:11,,1324512026,7/16/2014 22:26:39,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],and,n/a,82,59,95,77,-1,RO-has_causative_agent,903515-FS1,Soaking dentures in denture cleanser reduced the degree of DENTURE STOMATITIS and DENTURE PLAQUE.,DENTURE PLAQUE,DENTURE STOMATITIS
503669138,7/16/2014 22:43:55,,1324518971,7/16/2014 22:43:29,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],and,N/A,82,59,95,77,-1,RO-has_causative_agent,903515-FS1,Soaking dentures in denture cleanser reduced the degree of DENTURE STOMATITIS and DENTURE PLAQUE.,DENTURE PLAQUE,DENTURE STOMATITIS
503669138,7/16/2014 23:16:04,,1324531001,7/16/2014 23:15:50,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,list,82,59,95,77,-1,RO-has_causative_agent,903515-FS1,Soaking dentures in denture cleanser reduced the degree of DENTURE STOMATITIS and DENTURE PLAQUE.,DENTURE PLAQUE,DENTURE STOMATITIS
503669138,7/16/2014 23:21:25,,1324533717,7/16/2014 23:20:57,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[NONE],[NONE],N/A,two dif types of denture problems,82,59,95,77,-1,RO-has_causative_agent,903515-FS1,Soaking dentures in denture cleanser reduced the degree of DENTURE STOMATITIS and DENTURE PLAQUE.,DENTURE PLAQUE,DENTURE STOMATITIS
503669138,7/16/2014 23:21:28,,1324533742,7/16/2014 23:20:54,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated items,82,59,95,77,-1,RO-has_causative_agent,903515-FS1,Soaking dentures in denture cleanser reduced the degree of DENTURE STOMATITIS and DENTURE PLAQUE.,DENTURE PLAQUE,DENTURE STOMATITIS
503669139,7/16/2014 21:19:16,,1324485537,7/16/2014 21:18:24,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],involved with,N/A,70,36,90,52,-1,RO-disease_may_have_finding,902900-FS1,The study involved 12 patients with PHEOCHROMOCYTOMA 17 patients with ARTERIAL HYPERTENSION and 9 patients with borderline hypertension.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
503669139,7/16/2014 21:24:20,,1324487719,7/16/2014 21:24:01,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[ASSOCIATED_WITH],[ASSOCIATED_WITH],involved,N/A,70,36,90,52,-1,RO-disease_may_have_finding,902900-FS1,The study involved 12 patients with PHEOCHROMOCYTOMA 17 patients with ARTERIAL HYPERTENSION and 9 patients with borderline hypertension.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
503669139,7/16/2014 21:25:55,,1324488477,7/16/2014 21:25:23,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],HYPERTENSION,N/A,70,36,90,52,-1,RO-disease_may_have_finding,902900-FS1,The study involved 12 patients with PHEOCHROMOCYTOMA 17 patients with ARTERIAL HYPERTENSION and 9 patients with borderline hypertension.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
503669139,7/16/2014 21:26:07,,1324488530,7/16/2014 21:25:43,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],study,N/A,70,36,90,52,-1,RO-disease_may_have_finding,902900-FS1,The study involved 12 patients with PHEOCHROMOCYTOMA 17 patients with ARTERIAL HYPERTENSION and 9 patients with borderline hypertension.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
503669139,7/16/2014 21:28:55,,1324489728,7/16/2014 21:27:59,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PHEOCHROMOCYTOMA ARTERIAL HYPERTENSION,N/A,70,36,90,52,-1,RO-disease_may_have_finding,902900-FS1,The study involved 12 patients with PHEOCHROMOCYTOMA 17 patients with ARTERIAL HYPERTENSION and 9 patients with borderline hypertension.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
503669139,7/16/2014 21:32:23,,1324491029,7/16/2014 21:31:20,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[NONE],[NONE],N/A,Separate tests,70,36,90,52,-1,RO-disease_may_have_finding,902900-FS1,The study involved 12 patients with PHEOCHROMOCYTOMA 17 patients with ARTERIAL HYPERTENSION and 9 patients with borderline hypertension.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
503669139,7/16/2014 21:33:08,,1324491250,7/16/2014 21:32:46,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],involved 12 patients with PHEOCHROMOCYTOMA 17 patients with ARTERIAL HYPERTENSION,N/A,70,36,90,52,-1,RO-disease_may_have_finding,902900-FS1,The study involved 12 patients with PHEOCHROMOCYTOMA 17 patients with ARTERIAL HYPERTENSION and 9 patients with borderline hypertension.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
503669139,7/16/2014 21:36:37,,1324492750,7/16/2014 21:36:22,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CONTRAINDICATES],[CONTRAINDICATES],PHEOCHROMOCYTOMA,asd,70,36,90,52,-1,RO-disease_may_have_finding,902900-FS1,The study involved 12 patients with PHEOCHROMOCYTOMA 17 patients with ARTERIAL HYPERTENSION and 9 patients with borderline hypertension.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
503669139,7/16/2014 21:40:02,,1324494024,7/16/2014 21:39:48,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[NONE],[NONE],N/A,Unrelated conditions,70,36,90,52,-1,RO-disease_may_have_finding,902900-FS1,The study involved 12 patients with PHEOCHROMOCYTOMA 17 patients with ARTERIAL HYPERTENSION and 9 patients with borderline hypertension.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
503669139,7/16/2014 22:00:48,,1324501993,7/16/2014 21:59:49,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,70,36,90,52,-1,RO-disease_may_have_finding,902900-FS1,The study involved 12 patients with PHEOCHROMOCYTOMA 17 patients with ARTERIAL HYPERTENSION and 9 patients with borderline hypertension.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
503669139,7/16/2014 22:00:58,,1324502053,7/16/2014 22:00:20,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[NONE],[NONE],na,separate afflictions,70,36,90,52,-1,RO-disease_may_have_finding,902900-FS1,The study involved 12 patients with PHEOCHROMOCYTOMA 17 patients with ARTERIAL HYPERTENSION and 9 patients with borderline hypertension.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
503669139,7/16/2014 22:01:15,,1324502168,7/16/2014 22:01:00,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],study involved patients with PHEOCHROMOCYTOMA ARTERIAL HYPERTENSION,N/A,70,36,90,52,-1,RO-disease_may_have_finding,902900-FS1,The study involved 12 patients with PHEOCHROMOCYTOMA 17 patients with ARTERIAL HYPERTENSION and 9 patients with borderline hypertension.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
503669139,7/16/2014 22:04:05,,1324503306,7/16/2014 22:03:11,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],study involved PHEOCHROMOCYTOMA ARTERIAL HYPERTENSION,n/a,70,36,90,52,-1,RO-disease_may_have_finding,902900-FS1,The study involved 12 patients with PHEOCHROMOCYTOMA 17 patients with ARTERIAL HYPERTENSION and 9 patients with borderline hypertension.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
503669139,7/16/2014 22:15:12,,1324507047,7/16/2014 22:14:29,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[SYMPTOM],[SYMPTOM],PHEOCHROMOCYTOMA patients with ARTERIAL HYPERTENSION,N/A,70,36,90,52,-1,RO-disease_may_have_finding,902900-FS1,The study involved 12 patients with PHEOCHROMOCYTOMA 17 patients with ARTERIAL HYPERTENSION and 9 patients with borderline hypertension.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
503669139,7/16/2014 22:37:21,,1324516527,7/16/2014 22:36:42,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],study involved,n/a,70,36,90,52,-1,RO-disease_may_have_finding,902900-FS1,The study involved 12 patients with PHEOCHROMOCYTOMA 17 patients with ARTERIAL HYPERTENSION and 9 patients with borderline hypertension.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
503669140,7/16/2014 21:19:29,,1324485609,7/16/2014 21:18:58,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[MANIFESTATION],[MANIFESTATION],manifestations,N/A,73,210,106,251,-1,RO-has_causative_agent,903835-FS1,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
503669140,7/16/2014 21:22:27,,1324486842,7/16/2014 21:21:44,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[MANIFESTATION],[MANIFESTATION],manifestations of infection in patients with the,N/A,73,210,106,251,-1,RO-has_causative_agent,903835-FS1,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
503669140,7/16/2014 21:24:22,,1324487729,7/16/2014 21:23:53,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],manifestations of,N/A,73,210,106,251,-1,RO-has_causative_agent,903835-FS1,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
503669140,7/16/2014 21:25:04,,1324488031,7/16/2014 21:24:27,instagc,1.0,13763729,USA,"","",75.182.89.225,[PART_OF],[PART_OF],diverse neurologic manifestations of in patients,N?A,73,210,106,251,-1,RO-has_causative_agent,903835-FS1,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
503669140,7/16/2014 21:28:18,,1324489439,7/16/2014 21:27:54,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in patients with,N/A,73,210,106,251,-1,RO-has_causative_agent,903835-FS1,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
503669140,7/16/2014 21:33:36,,1324491491,7/16/2014 21:33:18,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,73,210,106,251,-1,RO-has_causative_agent,903835-FS1,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
503669140,7/16/2014 21:36:18,,1324492625,7/16/2014 21:36:06,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[LOCATION],[LOCATION],manifestations HIV,asd,73,210,106,251,-1,RO-has_causative_agent,903835-FS1,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
503669140,7/16/2014 21:44:27,,1324495762,7/16/2014 21:43:19,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],understanding characteristics,n/a,73,210,106,251,-1,RO-has_causative_agent,903835-FS1,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
503669140,7/16/2014 21:47:36,,1324497068,7/16/2014 21:47:08,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[CAUSES],[CAUSES],HUMAN IMMUNODEFICIENCY VIRUS (HIV) manifestations of HIV with ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),N/A,73,210,106,251,-1,RO-has_causative_agent,903835-FS1,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
503669140,7/16/2014 21:52:50,,1324499148,7/16/2014 21:51:38,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HUMAN IMMUNODEFICIENCY VIRUS (HIV) ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),n/a,73,210,106,251,-1,RO-has_causative_agent,903835-FS1,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
503669140,7/16/2014 21:57:11,,1324500768,7/16/2014 21:56:27,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",is critical to appreciate manifestations of HIV infection,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],73,210,106,251,-1,RO-has_causative_agent,903835-FS1,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
503669140,7/16/2014 22:01:34,,1324502293,7/16/2014 22:00:43,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SIDE_EFFECT] [ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]
[SIDE_EFFECT]",diverse neurologic manifestations of HIV infection in patients with,N/A,73,210,106,251,-1,RO-has_causative_agent,903835-FS1,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
503669140,7/16/2014 22:07:09,,1324504254,7/16/2014 22:06:15,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",appreciate the diverse neurologic manifestations,Na,73,210,106,251,-1,RO-has_causative_agent,903835-FS1,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
503669140,7/16/2014 22:24:48,,1324510990,7/16/2014 22:24:28,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],HUMAN IMMUNODEFICIENCY VIRUS (HIV) manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),N/A,73,210,106,251,-1,RO-has_causative_agent,903835-FS1,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
503669140,7/16/2014 22:43:56,,1324518975,7/16/2014 22:43:32,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[SYMPTOM],[SYMPTOM],with,n/a,73,210,106,251,-1,RO-has_causative_agent,903835-FS1,An understanding of the biologic characteristics and cellular tropism of HUMAN IMMUNODEFICIENCY VIRUS (HIV) is critical to appreciate the diverse neurologic manifestations of HIV infection in patients with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS),HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
503669141,7/16/2014 21:20:22,,1324486017,7/16/2014 21:19:53,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],often confused with,N/A,56,95,64,109,-1,RO-disease_may_have_finding,902626-FS1,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
503669141,7/16/2014 21:25:00,,1324488018,7/16/2014 21:24:33,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],confused with,N/A,56,95,64,109,-1,RO-disease_may_have_finding,902626-FS1,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
503669141,7/16/2014 21:31:20,,1324490624,7/16/2014 21:31:02,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],which is often confused with,N/A,56,95,64,109,-1,RO-disease_may_have_finding,902626-FS1,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
503669141,7/16/2014 21:32:25,,1324491030,7/16/2014 21:32:07,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],often confused with,N?A,56,95,64,109,-1,RO-disease_may_have_finding,902626-FS1,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
503669141,7/16/2014 21:35:36,,1324492340,7/16/2014 21:34:13,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],is a,N/A,56,95,64,109,-1,RO-disease_may_have_finding,902626-FS1,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
503669141,7/16/2014 21:44:04,,1324495618,7/16/2014 21:43:40,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[NONE],[NONE],N/A,These conditions are not related,56,95,64,109,-1,RO-disease_may_have_finding,902626-FS1,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
503669141,7/16/2014 21:58:55,,1324501369,7/16/2014 21:57:50,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",is a rare cause of often confused with,[CAUSES] [ASSOCIATED_WITH],56,95,64,109,-1,RO-disease_may_have_finding,902626-FS1,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
503669141,7/16/2014 22:00:09,,1324501771,7/16/2014 21:59:46,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],which is often confused with,N/A,56,95,64,109,-1,RO-disease_may_have_finding,902626-FS1,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
503669141,7/16/2014 22:06:13,,1324504006,7/16/2014 22:05:44,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[ASSOCIATED_WITH],[ASSOCIATED_WITH],often confused with,Na,56,95,64,109,-1,RO-disease_may_have_finding,902626-FS1,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
503669141,7/16/2014 22:12:37,,1324506016,7/16/2014 22:12:03,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[NONE],[NONE],na,"separate conditions, not to be confused with each other",56,95,64,109,-1,RO-disease_may_have_finding,902626-FS1,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
503669141,7/16/2014 22:20:31,,1324509417,7/16/2014 22:19:03,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[NONE],[NONE],N/A,Two different diseases often thought of similarly.,56,95,64,109,-1,RO-disease_may_have_finding,902626-FS1,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
503669141,7/16/2014 22:30:18,,1324513402,7/16/2014 22:29:17,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[CONTRAINDICATES],[CONTRAINDICATES],confused with,n/a,56,95,64,109,-1,RO-disease_may_have_finding,902626-FS1,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
503669141,7/16/2014 22:50:42,,1324521504,7/16/2014 22:50:24,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[LOCATION],[LOCATION],Localized amyloidosis,N/A,56,95,64,109,-1,RO-disease_may_have_finding,902626-FS1,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
503669141,7/16/2014 23:08:51,,1324528259,7/16/2014 23:06:49,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[OTHER],[OTHER],confused with,similar,56,95,64,109,-1,RO-disease_may_have_finding,902626-FS1,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
503669141,7/16/2014 23:14:09,,1324530272,7/16/2014 23:13:50,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],often confused with,N/A,56,95,64,109,-1,RO-disease_may_have_finding,902626-FS1,Localized amyloidosis of the bladder is a rare cause of HEMATURIA which is often confused with BLADDER CANCER,HEMATURIA,BLADDER CANCER
503669142,7/16/2014 21:25:31,,1324488235,7/16/2014 21:25:18,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],in the,N/A,44,109,64,130,1,RO-disease_has_primary_anatomic_site,902308-FS1,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
503669142,7/16/2014 21:26:13,,1324488566,7/16/2014 21:25:51,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],PATELLO FEMORAL,asd,44,109,64,130,1,RO-disease_has_primary_anatomic_site,902308-FS1,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
503669142,7/16/2014 21:27:59,,1324489294,7/16/2014 21:27:50,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],performed for,N/A,44,109,64,130,1,RO-disease_has_primary_anatomic_site,902308-FS1,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
503669142,7/16/2014 21:28:37,,1324489549,7/16/2014 21:28:20,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[TREATS],[TREATS],performed,N/A,44,109,64,130,1,RO-disease_has_primary_anatomic_site,902308-FS1,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
503669142,7/16/2014 21:30:35,,1324490374,7/16/2014 21:30:03,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],after upper tibial osteotomy performed for,N/A,44,109,64,130,1,RO-disease_has_primary_anatomic_site,902308-FS1,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
503669142,7/16/2014 21:36:07,,1324492557,7/16/2014 21:35:50,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],for,N/A,44,109,64,130,1,RO-disease_has_primary_anatomic_site,902308-FS1,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
503669142,7/16/2014 21:41:46,,1324494691,7/16/2014 21:41:06,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[LOCATION],[LOCATION],performed,N/A,44,109,64,130,1,RO-disease_has_primary_anatomic_site,902308-FS1,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
503669142,7/16/2014 21:47:40,,1324497084,7/16/2014 21:47:12,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],performed for,[DIAGNOSE_BY_TEST_OR_DRUG],44,109,64,130,1,RO-disease_has_primary_anatomic_site,902308-FS1,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
503669142,7/16/2014 21:48:45,,1324497511,7/16/2014 21:48:22,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[TREATS],[TREATS],PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE,N/A,44,109,64,130,1,RO-disease_has_primary_anatomic_site,902308-FS1,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
503669142,7/16/2014 21:51:29,,1324498516,7/16/2014 21:51:03,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[LOCATION],[LOCATION],JOINT,n/a,44,109,64,130,1,RO-disease_has_primary_anatomic_site,902308-FS1,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
503669142,7/16/2014 21:56:57,,1324500684,7/16/2014 21:56:01,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],PATELLO FEMORAL JOINT osteotomy performed ARTHROSIS OF THE KNEE were studied,n/a,44,109,64,130,1,RO-disease_has_primary_anatomic_site,902308-FS1,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
503669142,7/16/2014 22:04:19,,1324503417,7/16/2014 22:03:58,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[LOCATION],[LOCATION],PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE,N/A,44,109,64,130,1,RO-disease_has_primary_anatomic_site,902308-FS1,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
503669142,7/16/2014 22:13:41,,1324506418,7/16/2014 22:12:42,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[LOCATION],[LOCATION],JOINT,na,44,109,64,130,1,RO-disease_has_primary_anatomic_site,902308-FS1,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
503669142,7/16/2014 22:23:41,,1324510590,7/16/2014 22:23:24,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE,N/A,44,109,64,130,1,RO-disease_has_primary_anatomic_site,902308-FS1,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
503669142,7/16/2014 22:30:49,,1324513660,7/16/2014 22:28:54,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[LOCATION] [ASSOCIATED_WITH],"[LOCATION]
[ASSOCIATED_WITH]",PATELLO FEMORAL JOINT after upper osteotomy performed for ARTHROSIS OF THE KNEE,N/A,44,109,64,130,1,RO-disease_has_primary_anatomic_site,902308-FS1,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
503669143,7/16/2014 21:19:20,,1324485565,7/16/2014 21:19:03,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[CAUSES],[CAUSES],cause,N/A,46,0,62,16,1,RO-has_manifestation,906470-FS1,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
503669143,7/16/2014 21:20:50,,1324486176,7/16/2014 21:20:24,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],infrequent cause of,N/A,46,0,62,16,1,RO-has_manifestation,906470-FS1,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
503669143,7/16/2014 21:23:52,,1324487501,7/16/2014 21:22:26,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES],[CAUSES],infrequent cause,N/A,46,0,62,16,1,RO-has_manifestation,906470-FS1,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
503669143,7/16/2014 21:25:03,,1324488030,7/16/2014 21:24:47,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],an infrequent cause of,N/A,46,0,62,16,1,RO-has_manifestation,906470-FS1,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
503669143,7/16/2014 21:32:06,,1324490906,7/16/2014 21:31:49,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],cause of,N/A,46,0,62,16,1,RO-has_manifestation,906470-FS1,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
503669143,7/16/2014 21:51:35,,1324498561,7/16/2014 21:51:02,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",an infrequent cause of,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],46,0,62,16,1,RO-has_manifestation,906470-FS1,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
503669143,7/16/2014 22:06:49,,1324504145,7/16/2014 22:06:21,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[CAUSES],[CAUSES],cause of,na,46,0,62,16,1,RO-has_manifestation,906470-FS1,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
503669143,7/16/2014 22:26:16,,1324511615,7/16/2014 22:25:56,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS",N/A,46,0,62,16,1,RO-has_manifestation,906470-FS1,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
503669143,7/16/2014 22:33:06,,1324514464,7/16/2014 22:32:39,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",cause,n/a,46,0,62,16,1,RO-has_manifestation,906470-FS1,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
503669143,7/16/2014 22:57:16,,1324524330,7/16/2014 22:57:07,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],cause,N/A,46,0,62,16,1,RO-has_manifestation,906470-FS1,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
503669143,7/16/2014 22:59:08,,1324524915,7/16/2014 22:58:34,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES],[CAUSES],cause of DIABETES,N/A,46,0,62,16,1,RO-has_manifestation,906470-FS1,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
503669143,7/16/2014 23:12:00,,1324529441,7/16/2014 23:11:47,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[CAUSES],[CAUSES],infrequent cause,N/A,46,0,62,16,1,RO-has_manifestation,906470-FS1,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
503669143,7/16/2014 23:21:50,,1324533928,7/16/2014 23:21:24,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],"WOLFRAM SYNDROME (WS), cause of DIABETES MELLITUS",N/A,46,0,62,16,1,RO-has_manifestation,906470-FS1,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
503669143,7/16/2014 23:23:46,,1324534976,7/16/2014 23:23:32,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[CAUSES],[CAUSES],an infrequent cause of,N/A,46,0,62,16,1,RO-has_manifestation,906470-FS1,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
503669143,7/16/2014 23:24:36,,1324535376,7/16/2014 23:24:15,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],an infrequent cause of,na,46,0,62,16,1,RO-has_manifestation,906470-FS1,"WOLFRAM SYNDROME (WS), an infrequent cause of DIABETES MELLITUS derives its name from the physician who first reported the combination of juvenile onset diabetes mellitus and optic atrophy.",DIABETES MELLITUS,WOLFRAM SYNDROME
503669144,7/16/2014 21:20:53,,1324486207,7/16/2014 21:20:34,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],or,N/A,93,7,117,14,-1,RO-cause_of,900292-FS1,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
503669144,7/16/2014 21:26:50,,1324488846,7/16/2014 21:26:17,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],HYPERSENSITIVITY REACTION during which the allergen,N/A,93,7,117,14,-1,RO-cause_of,900292-FS1,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
503669144,7/16/2014 21:27:16,,1324489069,7/16/2014 21:27:00,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SYMPTOM],[SYMPTOM],ETIOLOGY:,asd,93,7,117,14,-1,RO-cause_of,900292-FS1,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
503669144,7/16/2014 21:29:07,,1324489813,7/16/2014 21:28:04,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],result of,N/A,93,7,117,14,-1,RO-cause_of,900292-FS1,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
503669144,7/16/2014 21:29:53,,1324490170,7/16/2014 21:29:31,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[MANIFESTATION],[MANIFESTATION],condition,N/A,93,7,117,14,-1,RO-cause_of,900292-FS1,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
503669144,7/16/2014 21:38:10,,1324493241,7/16/2014 21:37:14,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],is the result of is absorbed,N/A,93,7,117,14,-1,RO-cause_of,900292-FS1,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
503669144,7/16/2014 21:42:28,,1324494906,7/16/2014 21:41:57,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[CAUSES],[CAUSES],is the result of,[CAUSES],93,7,117,14,-1,RO-cause_of,900292-FS1,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
503669144,7/16/2014 21:59:14,,1324501477,7/16/2014 21:58:40,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[IS_A],[IS_A],condition is the result a type allergic HYPERSENSITIVITY REACTION,N/A,93,7,117,14,-1,RO-cause_of,900292-FS1,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
503669144,7/16/2014 22:09:21,,1324504875,7/16/2014 22:08:34,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[CAUSES],[CAUSES],result of,Na,93,7,117,14,-1,RO-cause_of,900292-FS1,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
503669144,7/16/2014 22:12:00,,1324505776,7/16/2014 22:11:02,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH] [IS_A],"[ASSOCIATED_WITH]
[IS_A]",ALLERGY result type allergic HYPERSENSITIVITY REACTION,n/a,93,7,117,14,-1,RO-cause_of,900292-FS1,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
503669144,7/16/2014 22:24:26,,1324510846,7/16/2014 22:24:09,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],ALLERGY allergic or HYPERSENSITIVITY REACTION,N/A,93,7,117,14,-1,RO-cause_of,900292-FS1,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
503669144,7/16/2014 22:41:41,,1324518255,7/16/2014 22:41:23,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],type,n/a,93,7,117,14,-1,RO-cause_of,900292-FS1,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
503669144,7/16/2014 22:54:43,,1324523292,7/16/2014 22:53:36,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[MANIFESTATION],[MANIFESTATION],The condition,N/A,93,7,117,14,-1,RO-cause_of,900292-FS1,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
503669144,7/16/2014 23:15:20,,1324530686,7/16/2014 23:15:10,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,list,93,7,117,14,-1,RO-cause_of,900292-FS1,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
503669144,7/16/2014 23:20:06,,1324533020,7/16/2014 23:19:12,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[IS_A],[IS_A],The condition is the result of a type I allergic or,na,93,7,117,14,-1,RO-cause_of,900292-FS1,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
503669145,7/16/2014 21:20:40,,1324486100,7/16/2014 21:20:07,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],treated with,N/A,64,99,84,116,1,RO-may_treat,907885-FS1,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
503669145,7/16/2014 21:27:40,,1324489193,7/16/2014 21:27:32,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],treated with,N/A,64,99,84,116,1,RO-may_treat,907885-FS1,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
503669145,7/16/2014 21:29:00,,1324489763,7/16/2014 21:28:37,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treated,N/A,64,99,84,116,1,RO-may_treat,907885-FS1,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
503669145,7/16/2014 21:32:58,,1324491205,7/16/2014 21:32:25,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],treated with,N/A,64,99,84,116,1,RO-may_treat,907885-FS1,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
503669145,7/16/2014 21:34:53,,1324492008,7/16/2014 21:34:41,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SYMPTOM],[SYMPTOM],term follow,asd,64,99,84,116,1,RO-may_treat,907885-FS1,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
503669145,7/16/2014 21:36:39,,1324492762,7/16/2014 21:36:19,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],treated,N/A,64,99,84,116,1,RO-may_treat,907885-FS1,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
503669145,7/16/2014 21:44:43,,1324495878,7/16/2014 21:44:33,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[TREATS],[TREATS],MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL,N/A,64,99,84,116,1,RO-may_treat,907885-FS1,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
503669145,7/16/2014 21:46:58,,1324496847,7/16/2014 21:46:28,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL,n/a,64,99,84,116,1,RO-may_treat,907885-FS1,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
503669145,7/16/2014 21:48:37,,1324497433,7/16/2014 21:48:11,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[TREATS],[TREATS],treated with,[TREATS],64,99,84,116,1,RO-may_treat,907885-FS1,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
503669145,7/16/2014 21:59:11,,1324501454,7/16/2014 21:58:01,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[TREATS],[TREATS],treated with,Na,64,99,84,116,1,RO-may_treat,907885-FS1,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
503669145,7/16/2014 22:02:04,,1324502500,7/16/2014 22:00:03,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[TREATS],[TREATS],treated with,N/A,64,99,84,116,1,RO-may_treat,907885-FS1,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
503669145,7/16/2014 22:10:57,,1324505420,7/16/2014 22:10:29,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[TREATS],[TREATS],treated with,na,64,99,84,116,1,RO-may_treat,907885-FS1,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
503669145,7/16/2014 22:21:06,,1324509633,7/16/2014 22:20:48,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[TREATS],[TREATS],MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL,N/A,64,99,84,116,1,RO-may_treat,907885-FS1,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
503669145,7/16/2014 22:46:00,,1324519751,7/16/2014 22:45:41,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],treated with,N/A,64,99,84,116,1,RO-may_treat,907885-FS1,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
503669145,7/16/2014 23:04:18,,1324526730,7/16/2014 23:03:52,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],treated with,N/A,64,99,84,116,1,RO-may_treat,907885-FS1,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
503669146,7/16/2014 21:23:15,,1324487166,7/16/2014 21:22:56,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],including,N/A,108,83,124,97,-1,RO-cause_of,900011-FS1,"About one third of patients have a history of asthma, and up to one half have some ATOPIC HISTORY including ALLERGIC RHINITIS and nasal polyps.",ALLERGIC RHINITIS,ATOPIC HISTORY
503669146,7/16/2014 21:27:44,,1324489212,7/16/2014 21:27:26,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],including,N/A,108,83,124,97,-1,RO-cause_of,900011-FS1,"About one third of patients have a history of asthma, and up to one half have some ATOPIC HISTORY including ALLERGIC RHINITIS and nasal polyps.",ALLERGIC RHINITIS,ATOPIC HISTORY
503669146,7/16/2014 21:29:38,,1324490076,7/16/2014 21:29:23,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[PART_OF],[PART_OF],including,N/A,108,83,124,97,-1,RO-cause_of,900011-FS1,"About one third of patients have a history of asthma, and up to one half have some ATOPIC HISTORY including ALLERGIC RHINITIS and nasal polyps.",ALLERGIC RHINITIS,ATOPIC HISTORY
503669146,7/16/2014 21:31:52,,1324490828,7/16/2014 21:31:31,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],have some including,N/A,108,83,124,97,-1,RO-cause_of,900011-FS1,"About one third of patients have a history of asthma, and up to one half have some ATOPIC HISTORY including ALLERGIC RHINITIS and nasal polyps.",ALLERGIC RHINITIS,ATOPIC HISTORY
503669146,7/16/2014 22:01:56,,1324502444,7/16/2014 22:01:35,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PART_OF],[PART_OF],including,N/A,108,83,124,97,-1,RO-cause_of,900011-FS1,"About one third of patients have a history of asthma, and up to one half have some ATOPIC HISTORY including ALLERGIC RHINITIS and nasal polyps.",ALLERGIC RHINITIS,ATOPIC HISTORY
503669146,7/16/2014 22:02:36,,1324502729,7/16/2014 22:02:19,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],one half have some ATOPIC HISTORY including ALLERGIC RHINITIS,N/A,108,83,124,97,-1,RO-cause_of,900011-FS1,"About one third of patients have a history of asthma, and up to one half have some ATOPIC HISTORY including ALLERGIC RHINITIS and nasal polyps.",ALLERGIC RHINITIS,ATOPIC HISTORY
503669146,7/16/2014 22:28:51,,1324512859,7/16/2014 22:27:30,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[SYMPTOM],[SYMPTOM],have some ATOPIC HISTORY including ALLERGIC RHINITIS,N/A,108,83,124,97,-1,RO-cause_of,900011-FS1,"About one third of patients have a history of asthma, and up to one half have some ATOPIC HISTORY including ALLERGIC RHINITIS and nasal polyps.",ALLERGIC RHINITIS,ATOPIC HISTORY
503669146,7/16/2014 22:46:37,,1324520006,7/16/2014 22:45:59,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],including,n/a,108,83,124,97,-1,RO-cause_of,900011-FS1,"About one third of patients have a history of asthma, and up to one half have some ATOPIC HISTORY including ALLERGIC RHINITIS and nasal polyps.",ALLERGIC RHINITIS,ATOPIC HISTORY
503669146,7/16/2014 22:57:31,,1324524399,7/16/2014 22:57:18,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,N/A,108,83,124,97,-1,RO-cause_of,900011-FS1,"About one third of patients have a history of asthma, and up to one half have some ATOPIC HISTORY including ALLERGIC RHINITIS and nasal polyps.",ALLERGIC RHINITIS,ATOPIC HISTORY
503669146,7/16/2014 23:12:14,,1324529564,7/16/2014 23:12:03,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,N/A,108,83,124,97,-1,RO-cause_of,900011-FS1,"About one third of patients have a history of asthma, and up to one half have some ATOPIC HISTORY including ALLERGIC RHINITIS and nasal polyps.",ALLERGIC RHINITIS,ATOPIC HISTORY
503669146,7/16/2014 23:17:53,,1324531844,7/16/2014 23:17:36,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[PART_OF],[PART_OF],including,N/A,108,83,124,97,-1,RO-cause_of,900011-FS1,"About one third of patients have a history of asthma, and up to one half have some ATOPIC HISTORY including ALLERGIC RHINITIS and nasal polyps.",ALLERGIC RHINITIS,ATOPIC HISTORY
503669146,7/16/2014 23:20:38,,1324533291,7/16/2014 23:20:13,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[PART_OF],[PART_OF],ATOPIC HISTORY including ALLERGIC RHINITIS,N/A,108,83,124,97,-1,RO-cause_of,900011-FS1,"About one third of patients have a history of asthma, and up to one half have some ATOPIC HISTORY including ALLERGIC RHINITIS and nasal polyps.",ALLERGIC RHINITIS,ATOPIC HISTORY
503669146,7/16/2014 23:23:36,,1324534854,7/16/2014 23:23:05,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[IS_A],[IS_A],including,na,108,83,124,97,-1,RO-cause_of,900011-FS1,"About one third of patients have a history of asthma, and up to one half have some ATOPIC HISTORY including ALLERGIC RHINITIS and nasal polyps.",ALLERGIC RHINITIS,ATOPIC HISTORY
503669146,7/16/2014 23:31:23,,1324538191,7/16/2014 23:31:05,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[PART_OF],[PART_OF],including,n/a,108,83,124,97,-1,RO-cause_of,900011-FS1,"About one third of patients have a history of asthma, and up to one half have some ATOPIC HISTORY including ALLERGIC RHINITIS and nasal polyps.",ALLERGIC RHINITIS,ATOPIC HISTORY
503669146,7/16/2014 23:32:27,,1324538682,7/16/2014 23:31:54,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[SYMPTOM],[SYMPTOM],including,na,108,83,124,97,-1,RO-cause_of,900011-FS1,"About one third of patients have a history of asthma, and up to one half have some ATOPIC HISTORY including ALLERGIC RHINITIS and nasal polyps.",ALLERGIC RHINITIS,ATOPIC HISTORY
503669147,7/16/2014 21:18:47,,1324485358,7/16/2014 21:18:22,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[PART_OF],[PART_OF],that is present in,N/A,131,171,150,183,1,RO-has_ingredient,905786-FS1,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
503669147,7/16/2014 21:20:05,,1324485887,7/16/2014 21:19:53,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],that is present in,N/A,131,171,150,183,1,RO-has_ingredient,905786-FS1,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
503669147,7/16/2014 21:27:53,,1324489258,7/16/2014 21:27:16,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[ASSOCIATED_WITH],[ASSOCIATED_WITH],that is present,N/A,131,171,150,183,1,RO-has_ingredient,905786-FS1,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
503669147,7/16/2014 21:28:04,,1324489324,7/16/2014 21:27:41,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[PREVENTS],[PREVENTS],present,N/A,131,171,150,183,1,RO-has_ingredient,905786-FS1,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
503669147,7/16/2014 21:30:41,,1324490408,7/16/2014 21:30:18,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],present in,N/A,131,171,150,183,1,RO-has_ingredient,905786-FS1,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
503669147,7/16/2014 21:32:45,,1324491163,7/16/2014 21:32:26,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],is present in,N/A,131,171,150,183,1,RO-has_ingredient,905786-FS1,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
503669147,7/16/2014 21:34:25,,1324491865,7/16/2014 21:34:01,clixsense,1.0,15189335,GBR,H9,London,188.29.164.50,[CAUSES],[CAUSES],due to,Na,131,171,150,183,1,RO-has_ingredient,905786-FS1,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
503669147,7/16/2014 21:35:14,,1324492156,7/16/2014 21:34:56,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SIDE_EFFECT],[SIDE_EFFECT],polypeptide observed,asd,131,171,150,183,1,RO-has_ingredient,905786-FS1,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
503669147,7/16/2014 21:39:36,,1324493828,7/16/2014 21:38:11,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is present in,N/A,131,171,150,183,1,RO-has_ingredient,905786-FS1,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
503669147,7/16/2014 21:41:05,,1324494442,7/16/2014 21:40:29,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[OTHER],[OTHER],absence of P CYCLOPIUM PROTEASE that is present in PROTEINASE K,N/A,131,171,150,183,1,RO-has_ingredient,905786-FS1,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
503669147,7/16/2014 21:47:08,,1324496923,7/16/2014 21:46:38,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[LOCATION],[LOCATION],is present in,[LOCATION],131,171,150,183,1,RO-has_ingredient,905786-FS1,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
503669147,7/16/2014 22:01:46,,1324502373,7/16/2014 22:01:15,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[PART_OF],[PART_OF],the P CYCLOPIUM PROTEASE that is present in PROTEINASE K,N/A,131,171,150,183,1,RO-has_ingredient,905786-FS1,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
503669147,7/16/2014 22:16:15,,1324507504,7/16/2014 22:15:44,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[NONE],[NONE],na,separate,131,171,150,183,1,RO-has_ingredient,905786-FS1,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
503669147,7/16/2014 22:25:55,,1324511436,7/16/2014 22:25:34,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[NONE],[NONE],N/A,N/A,131,171,150,183,1,RO-has_ingredient,905786-FS1,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
503669147,7/16/2014 22:49:09,,1324520923,7/16/2014 22:48:13,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],that is present in,n/a,131,171,150,183,1,RO-has_ingredient,905786-FS1,"The greatest variation from the proteinase K polypeptide is in loop 114 134 and is due to the absence of a disulfide bridge in the P CYCLOPIUM PROTEASE that is present in PROTEINASE K A difference was also observed in the orientation of the histidine in the catalytic triad, though this could be due to the presence of PMSF at the active site.",P CYCLOPIUM PROTEASE,PROTEINASE K
503669148,7/16/2014 21:18:57,,1324485402,7/16/2014 21:18:28,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],study,N/A,32,0,48,11,1,RO-may_treat,907569-FS1,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
503669148,7/16/2014 21:19:05,,1324485494,7/16/2014 21:18:44,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],in the treatment of,N/A,32,0,48,11,1,RO-may_treat,907569-FS1,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
503669148,7/16/2014 21:19:52,,1324485803,7/16/2014 21:19:44,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],in the treatment,N/A,32,0,48,11,1,RO-may_treat,907569-FS1,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
503669148,7/16/2014 21:31:00,,1324490515,7/16/2014 21:30:49,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],POLYCYTHEMIA VERA:,asd,32,0,48,11,1,RO-may_treat,907569-FS1,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
503669148,7/16/2014 21:31:06,,1324490542,7/16/2014 21:30:28,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],in the treatment of,N/A,32,0,48,11,1,RO-may_treat,907569-FS1,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
503669148,7/16/2014 21:35:17,,1324492203,7/16/2014 21:35:03,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],treatment,N/A,32,0,48,11,1,RO-may_treat,907569-FS1,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
503669148,7/16/2014 21:46:22,,1324496625,7/16/2014 21:46:02,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[TREATS],[TREATS],HYDROXYUREA in treatment of POLYCYTHEMIA VERA:,N/A,32,0,48,11,1,RO-may_treat,907569-FS1,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
503669148,7/16/2014 21:48:08,,1324497262,7/16/2014 21:47:42,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[TREATS],[TREATS],in the treatment of,[TREATS],32,0,48,11,1,RO-may_treat,907569-FS1,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
503669148,7/16/2014 21:57:54,,1324501016,7/16/2014 21:57:27,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[TREATS],[TREATS],treatment of,Na,32,0,48,11,1,RO-may_treat,907569-FS1,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
503669148,7/16/2014 22:20:31,,1324509418,7/16/2014 22:20:02,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[TREATS],[TREATS],treatment of,na,32,0,48,11,1,RO-may_treat,907569-FS1,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
503669148,7/16/2014 22:25:05,,1324511071,7/16/2014 22:24:49,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[TREATS],[TREATS],HYDROXYUREA in the treatment of POLYCYTHEMIA VERA:,N/A,32,0,48,11,1,RO-may_treat,907569-FS1,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
503669148,7/16/2014 22:28:13,,1324512582,7/16/2014 22:27:13,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],treatment,n/a,32,0,48,11,1,RO-may_treat,907569-FS1,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
503669148,7/16/2014 22:45:09,,1324519385,7/16/2014 22:44:48,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],in the treatment of,N/A,32,0,48,11,1,RO-may_treat,907569-FS1,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
503669148,7/16/2014 23:01:03,,1324525525,7/16/2014 23:00:44,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],in the treatment,N/A,32,0,48,11,1,RO-may_treat,907569-FS1,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
503669148,7/16/2014 23:11:17,,1324529171,7/16/2014 23:11:06,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[TREATS],[TREATS],treatment,N/A,32,0,48,11,1,RO-may_treat,907569-FS1,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
503669149,7/16/2014 21:22:28,,1324486864,7/16/2014 21:22:02,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],localized,N/A,0,0,7,20,-1,RO-has_causative_agent,903841-FS1,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
503669149,7/16/2014 21:26:58,,1324488921,7/16/2014 21:26:35,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[SYMPTOM],[SYMPTOM],occasionally occurs,N/A,0,0,7,20,-1,RO-has_causative_agent,903841-FS1,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
503669149,7/16/2014 21:27:31,,1324489156,7/16/2014 21:27:22,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],occasionally occurs,N/A,0,0,7,20,-1,RO-has_causative_agent,903841-FS1,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
503669149,7/16/2014 21:34:25,,1324491874,7/16/2014 21:34:15,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],localized,N/A,0,0,7,20,-1,RO-has_causative_agent,903841-FS1,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
503669149,7/16/2014 21:44:05,,1324495628,7/16/2014 21:43:32,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[LOCATION],[LOCATION],localized,N/A,0,0,7,20,-1,RO-has_causative_agent,903841-FS1,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
503669149,7/16/2014 21:45:25,,1324496232,7/16/2014 21:44:46,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[MANIFESTATION],[MANIFESTATION],occurs as a,n/a,0,0,7,20,-1,RO-has_causative_agent,903841-FS1,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
503669149,7/16/2014 21:47:45,,1324497118,7/16/2014 21:46:59,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION] [LOCATION],"[LOCATION]
[MANIFESTATION]",MECONIUM PERITONITIS occasionally occurs as localized collection MECONIUM,n/a,0,0,7,20,-1,RO-has_causative_agent,903841-FS1,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
503669149,7/16/2014 21:55:17,,1324500141,7/16/2014 21:54:56,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[LOCATION],[LOCATION],localized collection,N/A,0,0,7,20,-1,RO-has_causative_agent,903841-FS1,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
503669149,7/16/2014 22:03:23,,1324503043,7/16/2014 22:02:35,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[CAUSES],[CAUSES],occurs as,N/A,0,0,7,20,-1,RO-has_causative_agent,903841-FS1,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
503669149,7/16/2014 22:08:48,,1324504760,7/16/2014 22:07:50,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[LOCATION],[LOCATION],localized collection of,na,0,0,7,20,-1,RO-has_causative_agent,903841-FS1,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
503669149,7/16/2014 22:11:22,,1324505515,7/16/2014 22:10:54,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[IS_A],[IS_A],occasionally occurs as,Na,0,0,7,20,-1,RO-has_causative_agent,903841-FS1,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
503669149,7/16/2014 23:09:37,,1324528556,7/16/2014 23:09:23,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],occurs as a,N/A,0,0,7,20,-1,RO-has_causative_agent,903841-FS1,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
503669149,7/16/2014 23:12:33,,1324529685,7/16/2014 23:10:24,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[SYMPTOM],[SYMPTOM],occurs,N/A,0,0,7,20,-1,RO-has_causative_agent,903841-FS1,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
503669149,7/16/2014 23:20:12,,1324533061,7/16/2014 23:19:40,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION],[MANIFESTATION],MECONIUM PERITONITIS occurs as collection of MECONIUM,N/A,0,0,7,20,-1,RO-has_causative_agent,903841-FS1,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
503669149,7/16/2014 23:20:56,,1324533446,7/16/2014 23:20:28,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[LOCATION],[LOCATION],occurs as a localized collection of,N/A,0,0,7,20,-1,RO-has_causative_agent,903841-FS1,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
503669150,7/16/2014 21:20:05,,1324485893,7/16/2014 21:19:42,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],on patients at high risk for,N/A,98,53,105,68,1,RO-may_diagnose,906639-FS1,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
503669150,7/16/2014 21:24:53,,1324487957,7/16/2014 21:24:37,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],perform TESTING,N/A,98,53,105,68,1,RO-may_diagnose,906639-FS1,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
503669150,7/16/2014 21:30:13,,1324490261,7/16/2014 21:29:56,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],improve,N/A,98,53,105,68,1,RO-may_diagnose,906639-FS1,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
503669150,7/16/2014 21:37:26,,1324493000,7/16/2014 21:37:12,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SYMPTOM],[SYMPTOM],quality care,asd,98,53,105,68,1,RO-may_diagnose,906639-FS1,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
503669150,7/16/2014 21:39:09,,1324493613,7/16/2014 21:38:52,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],GLUCOSE TESTING on patients at high risk for DIABETES,N/A,98,53,105,68,1,RO-may_diagnose,906639-FS1,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
503669150,7/16/2014 21:57:47,,1324500976,7/16/2014 21:57:14,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",on patients at high risk,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],98,53,105,68,1,RO-may_diagnose,906639-FS1,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
503669150,7/16/2014 22:02:20,,1324502627,7/16/2014 22:01:57,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TESTING on patients high risk for,N/A,98,53,105,68,1,RO-may_diagnose,906639-FS1,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
503669150,7/16/2014 22:09:52,,1324505042,7/16/2014 22:09:23,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to perform,Na,98,53,105,68,1,RO-may_diagnose,906639-FS1,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
503669150,7/16/2014 22:11:25,,1324505552,7/16/2014 22:11:01,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TESTING,na,98,53,105,68,1,RO-may_diagnose,906639-FS1,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
503669150,7/16/2014 22:16:22,,1324507576,7/16/2014 22:15:55,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],GLUCOSE TESTING on patients at high risk for DIABETES,N/A,98,53,105,68,1,RO-may_diagnose,906639-FS1,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
503669150,7/16/2014 22:43:30,,1324518850,7/16/2014 22:42:59,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],perform on patients at high risk for,n/a,98,53,105,68,1,RO-may_diagnose,906639-FS1,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
503669150,7/16/2014 22:47:31,,1324520434,7/16/2014 22:47:11,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[PREVENTS],[PREVENTS],perform,N/A,98,53,105,68,1,RO-may_diagnose,906639-FS1,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
503669150,7/16/2014 22:52:28,,1324522271,7/16/2014 22:51:27,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],improve quality of care,N/A,98,53,105,68,1,RO-may_diagnose,906639-FS1,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
503669150,7/16/2014 23:09:08,,1324528353,7/16/2014 23:08:57,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TESTING,N/A,98,53,105,68,1,RO-may_diagnose,906639-FS1,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
503669150,7/16/2014 23:21:51,,1324533936,7/16/2014 23:21:27,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],perform on patients at high risk for,N/A,98,53,105,68,1,RO-may_diagnose,906639-FS1,One way to improve the quality of care is to perform GLUCOSE TESTING on patients at high risk for DIABETES and to obtain complete lipid profiles.,DIABETES,GLUCOSE TESTING
503669151,7/16/2014 21:21:05,,1324486284,7/16/2014 21:20:54,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES],[CAUSES],result from,N/A,9,46,23,70,1,RO-disease_has_finding,901900-FS1,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
503669151,7/16/2014 21:27:10,,1324489020,7/16/2014 21:26:56,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],can also result from,N/A,9,46,23,70,1,RO-disease_has_finding,901900-FS1,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
503669151,7/16/2014 21:27:27,,1324489124,7/16/2014 21:26:38,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],can result,N/A,9,46,23,70,1,RO-disease_has_finding,901900-FS1,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
503669151,7/16/2014 21:31:46,,1324490788,7/16/2014 21:31:33,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],can also result from,N/A,9,46,23,70,1,RO-disease_has_finding,901900-FS1,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
503669151,7/16/2014 21:32:04,,1324490892,7/16/2014 21:31:52,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],LYMPHADENOPATHY MONONUCLEOSIS,asd,9,46,23,70,1,RO-disease_has_finding,901900-FS1,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
503669151,7/16/2014 21:39:21,,1324493682,7/16/2014 21:39:00,clixsense,1.0,15189335,GBR,H9,London,188.29.165.50,[CAUSES],[CAUSES],also result from,Na,9,46,23,70,1,RO-disease_has_finding,901900-FS1,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
503669151,7/16/2014 21:49:37,,1324497790,7/16/2014 21:49:26,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[CAUSES],[CAUSES],LYMPHADENOPATHY can result from INFECTIOUS MONONUCLEOSIS,N/A,9,46,23,70,1,RO-disease_has_finding,901900-FS1,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
503669151,7/16/2014 21:54:20,,1324499795,7/16/2014 21:53:51,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[MANIFESTATION],[MANIFESTATION],can also result from,[MANIFESTATION],9,46,23,70,1,RO-disease_has_finding,901900-FS1,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
503669151,7/16/2014 22:11:01,,1324505437,7/16/2014 22:10:30,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[CAUSES],[CAUSES],LYMPHADENOPATHY result from INFECTIOUS MONONUCLEOSIS,n/a,9,46,23,70,1,RO-disease_has_finding,901900-FS1,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
503669151,7/16/2014 22:19:57,,1324509106,7/16/2014 22:19:31,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[CAUSES],[CAUSES],result from,na,9,46,23,70,1,RO-disease_has_finding,901900-FS1,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
503669151,7/16/2014 22:27:06,,1324512005,7/16/2014 22:26:53,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS,N/A,9,46,23,70,1,RO-disease_has_finding,901900-FS1,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
503669151,7/16/2014 22:46:30,,1324519973,7/16/2014 22:46:01,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",can also result,N/A,9,46,23,70,1,RO-disease_has_finding,901900-FS1,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
503669151,7/16/2014 22:46:53,,1324520117,7/16/2014 22:46:35,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],result,N/A,9,46,23,70,1,RO-disease_has_finding,901900-FS1,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
503669151,7/16/2014 23:03:00,,1324526219,7/16/2014 23:02:37,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES],[CAUSES],can also result,N/A,9,46,23,70,1,RO-disease_has_finding,901900-FS1,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
503669151,7/16/2014 23:09:23,,1324528436,7/16/2014 23:09:09,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[CAUSES],[CAUSES],result from,N/A,9,46,23,70,1,RO-disease_has_finding,901900-FS1,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
503669152,7/16/2014 21:30:15,,1324490264,7/16/2014 21:30:03,clixsense,1,20614047,USA,MO,Maryville,174.32.162.147,[LOCATION],[LOCATION],AMYLOIDOSIS,asd,222,153,253,174,-1,RO-disease_has_finding,901669-FS1,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and SECONDARY AMYLOIDOSIS but has not been described in association with TRANSTHYRETIN AMYLOID DEPOSITION",TRANSTHYRETIN AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS
503669152,7/16/2014 21:32:19,,1324491015,7/16/2014 21:31:20,tremorgames,1,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],described in association with,N/A,222,153,253,174,-1,RO-disease_has_finding,901669-FS1,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and SECONDARY AMYLOIDOSIS but has not been described in association with TRANSTHYRETIN AMYLOID DEPOSITION",TRANSTHYRETIN AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS
503669152,7/16/2014 21:38:54,,1324493503,7/16/2014 21:38:21,tremorgames,1,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in association,N/A,222,153,253,174,-1,RO-disease_has_finding,901669-FS1,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and SECONDARY AMYLOIDOSIS but has not been described in association with TRANSTHYRETIN AMYLOID DEPOSITION",TRANSTHYRETIN AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS
503669152,7/16/2014 21:46:01,,1324496479,7/16/2014 21:45:28,elite,1,28503042,USA,OK,Watonga,65.255.78.241,[NONE],[NONE],N/A,Different conditions that are unrelated,222,153,253,174,-1,RO-disease_has_finding,901669-FS1,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and SECONDARY AMYLOIDOSIS but has not been described in association with TRANSTHYRETIN AMYLOID DEPOSITION",TRANSTHYRETIN AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS
503669152,7/16/2014 21:57:00,,1324500723,7/16/2014 21:56:31,neodev,1,12115558,USA,OH,Twinsburg,75.187.196.41,[CONTRAINDICATES],[CONTRAINDICATES],but has not been described in association,N/A,222,153,253,174,-1,RO-disease_has_finding,901669-FS1,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and SECONDARY AMYLOIDOSIS but has not been described in association with TRANSTHYRETIN AMYLOID DEPOSITION",TRANSTHYRETIN AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS
503669152,7/16/2014 22:03:10,,1324502972,7/16/2014 22:02:32,neodev,1,11460728,CAN,BC,Burnaby,70.79.16.165,[NONE],[NONE],none,not related,222,153,253,174,-1,RO-disease_has_finding,901669-FS1,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and SECONDARY AMYLOIDOSIS but has not been described in association with TRANSTHYRETIN AMYLOID DEPOSITION",TRANSTHYRETIN AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS
503669152,7/16/2014 22:04:24,,1324503437,7/16/2014 22:03:14,instagc,1,28519532,USA,IA,Honey Creek,12.73.110.61,[NONE],[NONE],na,but has not been described in association with,222,153,253,174,-1,RO-disease_has_finding,901669-FS1,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and SECONDARY AMYLOIDOSIS but has not been described in association with TRANSTHYRETIN AMYLOID DEPOSITION",TRANSTHYRETIN AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS
503669152,7/16/2014 22:10:56,,1324505421,7/16/2014 22:09:32,neodev,1,20929875,USA,MA,Boston,96.233.18.114,[NONE],[NONE],N/A,but has not been described in association with TRANSTHYRETIN AMYLOID DEPOSITION,222,153,253,174,-1,RO-disease_has_finding,901669-FS1,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and SECONDARY AMYLOIDOSIS but has not been described in association with TRANSTHYRETIN AMYLOID DEPOSITION",TRANSTHYRETIN AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS
503669152,7/16/2014 22:16:49,,1324507761,7/16/2014 22:16:23,clixsense,1,16827630,GBR,A7,Birmingham,86.146.169.103,[ASSOCIATED_WITH],[ASSOCIATED_WITH],primary and SECONDARY AMYLOIDOSIS but has not been described in association with TRANSTHYRETIN AMYLOID DEPOSITION,N/A,222,153,253,174,-1,RO-disease_has_finding,901669-FS1,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and SECONDARY AMYLOIDOSIS but has not been described in association with TRANSTHYRETIN AMYLOID DEPOSITION",TRANSTHYRETIN AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS
503669152,7/16/2014 22:41:21,,1324518177,7/16/2014 22:40:41,prodege,1,15439740,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],association,n/a,222,153,253,174,-1,RO-disease_has_finding,901669-FS1,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and SECONDARY AMYLOIDOSIS but has not been described in association with TRANSTHYRETIN AMYLOID DEPOSITION",TRANSTHYRETIN AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS
503669152,7/16/2014 23:05:31,,1324527147,7/16/2014 23:05:04,clixsense,1,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES],[CAUSES],enlargement of the thyroid gland,N/A,222,153,253,174,-1,RO-disease_has_finding,901669-FS1,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and SECONDARY AMYLOIDOSIS but has not been described in association with TRANSTHYRETIN AMYLOID DEPOSITION",TRANSTHYRETIN AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS
503669152,7/16/2014 23:11:47,,1324529350,7/16/2014 23:11:34,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,list,222,153,253,174,-1,RO-disease_has_finding,901669-FS1,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and SECONDARY AMYLOIDOSIS but has not been described in association with TRANSTHYRETIN AMYLOID DEPOSITION",TRANSTHYRETIN AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS
503669152,7/16/2014 23:18:18,,1324532015,7/16/2014 23:16:25,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],association with,N/A,222,153,253,174,-1,RO-disease_has_finding,901669-FS1,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and SECONDARY AMYLOIDOSIS but has not been described in association with TRANSTHYRETIN AMYLOID DEPOSITION",TRANSTHYRETIN AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS
503669152,7/16/2014 23:19:53,,1324532863,7/16/2014 23:19:04,zoombucks,1,4688131,CAN,BC,Vancouver,108.180.143.28,[CONTRAINDICATES],[CONTRAINDICATES],but has not been described in association with,N/A,222,153,253,174,-1,RO-disease_has_finding,901669-FS1,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and SECONDARY AMYLOIDOSIS but has not been described in association with TRANSTHYRETIN AMYLOID DEPOSITION",TRANSTHYRETIN AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS
503669152,7/16/2014 23:23:29,,1324534767,7/16/2014 23:23:05,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SECONDARY AMYLOIDOSIS in association with TRANSTHYRETIN AMYLOID DEPOSITION,N/A,222,153,253,174,-1,RO-disease_has_finding,901669-FS1,"Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and SECONDARY AMYLOIDOSIS but has not been described in association with TRANSTHYRETIN AMYLOID DEPOSITION",TRANSTHYRETIN AMYLOID DEPOSITION,SECONDARY AMYLOIDOSIS
503669153,7/16/2014 21:28:17,,1324489434,7/16/2014 21:28:03,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],followed by,N/A,68,172,89,189,-1,RO-disease_has_finding,901748-FS1,"Over the 5 year period, the most frequent phenotype encountered was SINGLE CRYPT DYSPLASIA (in all 5 colectomies from familial adenomatous polyposis patients), followed by SERRATED ADENOMAS (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",SINGLE CRYPT DYSPLASIA,SERRATED ADENOMAS
503669153,7/16/2014 21:33:00,,1324491221,7/16/2014 21:32:07,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],SERRATED ADENOMAS,asd,68,172,89,189,-1,RO-disease_has_finding,901748-FS1,"Over the 5 year period, the most frequent phenotype encountered was SINGLE CRYPT DYSPLASIA (in all 5 colectomies from familial adenomatous polyposis patients), followed by SERRATED ADENOMAS (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",SINGLE CRYPT DYSPLASIA,SERRATED ADENOMAS
503669153,7/16/2014 21:42:08,,1324494805,7/16/2014 21:41:38,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[NONE],[NONE],N/A,Different phenotypes,68,172,89,189,-1,RO-disease_has_finding,901748-FS1,"Over the 5 year period, the most frequent phenotype encountered was SINGLE CRYPT DYSPLASIA (in all 5 colectomies from familial adenomatous polyposis patients), followed by SERRATED ADENOMAS (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",SINGLE CRYPT DYSPLASIA,SERRATED ADENOMAS
503669153,7/16/2014 21:53:24,,1324499343,7/16/2014 21:52:54,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the most frequent phenotype encountered was SINGLE CRYPT DYSPLASIA followed by SERRATED ADENOMAS,N/A,68,172,89,189,-1,RO-disease_has_finding,901748-FS1,"Over the 5 year period, the most frequent phenotype encountered was SINGLE CRYPT DYSPLASIA (in all 5 colectomies from familial adenomatous polyposis patients), followed by SERRATED ADENOMAS (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",SINGLE CRYPT DYSPLASIA,SERRATED ADENOMAS
503669153,7/16/2014 22:02:39,,1324502756,7/16/2014 22:02:01,clixsense,1,15189335,GBR,H9,London,188.29.165.175,[IS_A],[IS_A],all 5 colectomies,Na,68,172,89,189,-1,RO-disease_has_finding,901748-FS1,"Over the 5 year period, the most frequent phenotype encountered was SINGLE CRYPT DYSPLASIA (in all 5 colectomies from familial adenomatous polyposis patients), followed by SERRATED ADENOMAS (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",SINGLE CRYPT DYSPLASIA,SERRATED ADENOMAS
503669153,7/16/2014 22:19:02,,1324508604,7/16/2014 22:18:33,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[ASSOCIATED_WITH],[ASSOCIATED_WITH],most frequent phenotype encountered was SINGLE CRYPT DYSPLASIA followed by SERRATED ADENOMAS,N/A,68,172,89,189,-1,RO-disease_has_finding,901748-FS1,"Over the 5 year period, the most frequent phenotype encountered was SINGLE CRYPT DYSPLASIA (in all 5 colectomies from familial adenomatous polyposis patients), followed by SERRATED ADENOMAS (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",SINGLE CRYPT DYSPLASIA,SERRATED ADENOMAS
503669153,7/16/2014 22:47:04,,1324520220,7/16/2014 22:46:31,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],followed by,N/A,68,172,89,189,-1,RO-disease_has_finding,901748-FS1,"Over the 5 year period, the most frequent phenotype encountered was SINGLE CRYPT DYSPLASIA (in all 5 colectomies from familial adenomatous polyposis patients), followed by SERRATED ADENOMAS (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",SINGLE CRYPT DYSPLASIA,SERRATED ADENOMAS
503669153,7/16/2014 22:49:31,,1324521050,7/16/2014 22:49:11,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],followed by,N/A,68,172,89,189,-1,RO-disease_has_finding,901748-FS1,"Over the 5 year period, the most frequent phenotype encountered was SINGLE CRYPT DYSPLASIA (in all 5 colectomies from familial adenomatous polyposis patients), followed by SERRATED ADENOMAS (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",SINGLE CRYPT DYSPLASIA,SERRATED ADENOMAS
503669153,7/16/2014 23:10:01,,1324528698,7/16/2014 23:09:50,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,list,68,172,89,189,-1,RO-disease_has_finding,901748-FS1,"Over the 5 year period, the most frequent phenotype encountered was SINGLE CRYPT DYSPLASIA (in all 5 colectomies from familial adenomatous polyposis patients), followed by SERRATED ADENOMAS (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",SINGLE CRYPT DYSPLASIA,SERRATED ADENOMAS
503669153,7/16/2014 23:21:24,,1324533683,7/16/2014 23:20:39,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SINGLE CRYPT followed by SERRATED ADENOMAS,N/A,68,172,89,189,-1,RO-disease_has_finding,901748-FS1,"Over the 5 year period, the most frequent phenotype encountered was SINGLE CRYPT DYSPLASIA (in all 5 colectomies from familial adenomatous polyposis patients), followed by SERRATED ADENOMAS (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",SINGLE CRYPT DYSPLASIA,SERRATED ADENOMAS
503669153,7/16/2014 23:24:14,,1324535215,7/16/2014 23:23:38,zoombucks,1,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated items,68,172,89,189,-1,RO-disease_has_finding,901748-FS1,"Over the 5 year period, the most frequent phenotype encountered was SINGLE CRYPT DYSPLASIA (in all 5 colectomies from familial adenomatous polyposis patients), followed by SERRATED ADENOMAS (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",SINGLE CRYPT DYSPLASIA,SERRATED ADENOMAS
503669153,7/16/2014 23:24:18,,1324535244,7/16/2014 23:23:47,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[OTHER],[OTHER],followed by,a list of diseases,68,172,89,189,-1,RO-disease_has_finding,901748-FS1,"Over the 5 year period, the most frequent phenotype encountered was SINGLE CRYPT DYSPLASIA (in all 5 colectomies from familial adenomatous polyposis patients), followed by SERRATED ADENOMAS (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",SINGLE CRYPT DYSPLASIA,SERRATED ADENOMAS
503669153,7/16/2014 23:31:04,,1324538016,7/16/2014 23:28:31,zapbux,1,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,One was followed by the other but they aren't linked to each other.,68,172,89,189,-1,RO-disease_has_finding,901748-FS1,"Over the 5 year period, the most frequent phenotype encountered was SINGLE CRYPT DYSPLASIA (in all 5 colectomies from familial adenomatous polyposis patients), followed by SERRATED ADENOMAS (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",SINGLE CRYPT DYSPLASIA,SERRATED ADENOMAS
503669153,7/16/2014 23:33:07,,1324538925,7/16/2014 23:32:28,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,[NONE],[NONE],n/a,no relation expresses,68,172,89,189,-1,RO-disease_has_finding,901748-FS1,"Over the 5 year period, the most frequent phenotype encountered was SINGLE CRYPT DYSPLASIA (in all 5 colectomies from familial adenomatous polyposis patients), followed by SERRATED ADENOMAS (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",SINGLE CRYPT DYSPLASIA,SERRATED ADENOMAS
503669153,7/17/2014 00:11:59,,1324555665,7/17/2014 00:11:31,neodev,1,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],followed by,N/A,68,172,89,189,-1,RO-disease_has_finding,901748-FS1,"Over the 5 year period, the most frequent phenotype encountered was SINGLE CRYPT DYSPLASIA (in all 5 colectomies from familial adenomatous polyposis patients), followed by SERRATED ADENOMAS (11.2%), hyperplastic polyps (8.4%), dysplasia in UC (6.3%), pure carcinoid tumours (1.7%), signet ring cell carcinoma (1.1%), adenocarcinoid tumours (0.2%) and de novo carcinomas (0.1%.",SINGLE CRYPT DYSPLASIA,SERRATED ADENOMAS
503669154,7/16/2014 21:23:44,,1324487462,7/16/2014 21:23:28,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],with a prepared formulation,N/A,70,152,106,176,1,RO-may_treat,908300-FS1,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
503669154,7/16/2014 21:28:55,,1324489735,7/16/2014 21:28:38,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[TREATS],[TREATS],treatment,N/A,70,152,106,176,1,RO-may_treat,908300-FS1,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
503669154,7/16/2014 21:29:25,,1324489985,7/16/2014 21:28:47,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],successful treatment of with a commercially prepared formulation of,N/A,70,152,106,176,1,RO-may_treat,908300-FS1,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
503669154,7/16/2014 21:30:16,,1324490269,7/16/2014 21:29:53,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],successful treatment of with,N/A,70,152,106,176,1,RO-may_treat,908300-FS1,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
503669154,7/16/2014 21:30:30,,1324490346,7/16/2014 21:30:18,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CONTRAINDICATES],[CONTRAINDICATES],treatment,asd,70,152,106,176,1,RO-may_treat,908300-FS1,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
503669154,7/16/2014 21:30:40,,1324490393,7/16/2014 21:30:22,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],prepared,N/A,70,152,106,176,1,RO-may_treat,908300-FS1,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
503669154,7/16/2014 21:32:01,,1324490883,7/16/2014 21:31:24,clixsense,1.0,15189335,GBR,H9,London,188.29.164.50,[TREATS],[TREATS],successful treatment,Na,70,152,106,176,1,RO-may_treat,908300-FS1,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
503669154,7/16/2014 21:40:29,,1324494211,7/16/2014 21:40:05,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[TREATS],[TREATS],treatment of patient with DRUG RESISTANT VISCERAL LEISHMANIASIS LIPOSOMAL AMPHOTERICIN B,N/A,70,152,106,176,1,RO-may_treat,908300-FS1,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
503669154,7/16/2014 21:52:53,,1324499172,7/16/2014 21:52:13,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],successful treatment of a patient with DRUG RESISTANT VISCERAL LEISHMANIASIS with LIPOSOMAL AMPHOTERICIN B,N/A,70,152,106,176,1,RO-may_treat,908300-FS1,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
503669154,7/16/2014 21:58:40,,1324501298,7/16/2014 21:58:10,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],commercially prepared,N/A,70,152,106,176,1,RO-may_treat,908300-FS1,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
503669154,7/16/2014 21:59:30,,1324501570,7/16/2014 21:58:56,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],with a commercially prepared formulation of,[DIAGNOSE_BY_TEST_OR_DRUG],70,152,106,176,1,RO-may_treat,908300-FS1,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
503669154,7/16/2014 22:02:40,,1324502759,7/16/2014 22:02:01,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[TREATS],[TREATS],treatment of with,na,70,152,106,176,1,RO-may_treat,908300-FS1,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
503669154,7/16/2014 22:09:32,,1324504934,7/16/2014 22:08:47,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],DRUG RESISTANT VISCERAL LEISHMANIASIS commercially prepared formulation LIPOSOMAL AMPHOTERICIN B,n/a,70,152,106,176,1,RO-may_treat,908300-FS1,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
503669154,7/16/2014 22:45:57,,1324519734,7/16/2014 22:45:01,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],successful treatment with multiply,n/a,70,152,106,176,1,RO-may_treat,908300-FS1,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
503669154,7/16/2014 22:48:50,,1324520844,7/16/2014 22:48:30,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,70,152,106,176,1,RO-may_treat,908300-FS1,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
503669155,7/16/2014 21:19:41,,1324485699,7/16/2014 21:19:27,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],the cause of,N/A,77,104,89,112,1,RO-has_causative_agent,903571-FS1,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
503669155,7/16/2014 21:24:36,,1324487872,7/16/2014 21:24:21,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[CAUSES],[CAUSES],cause,N/A,77,104,89,112,1,RO-has_causative_agent,903571-FS1,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
503669155,7/16/2014 21:24:54,,1324487973,7/16/2014 21:24:21,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],closest known virus to,N/A,77,104,89,112,1,RO-has_causative_agent,903571-FS1,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
503669155,7/16/2014 21:26:38,,1324488778,7/16/2014 21:26:17,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SYMPTOM],[SYMPTOM],same,asd,77,104,89,112,1,RO-has_causative_agent,903571-FS1,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
503669155,7/16/2014 21:27:40,,1324489198,7/16/2014 21:27:22,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],cause,N/A,77,104,89,112,1,RO-has_causative_agent,903571-FS1,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
503669155,7/16/2014 21:40:33,,1324494226,7/16/2014 21:39:38,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],is the cause of,N/A,77,104,89,112,1,RO-has_causative_agent,903571-FS1,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
503669155,7/16/2014 21:52:17,,1324498887,7/16/2014 21:51:38,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[CAUSES],[CAUSES],the cause of,[CAUSES],77,104,89,112,1,RO-has_causative_agent,903571-FS1,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
503669155,7/16/2014 21:54:55,,1324499993,7/16/2014 21:54:15,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER] [CAUSES],"[CAUSES]
[OTHER]",the cause of SMALLPOX,N/A,77,104,89,112,1,RO-has_causative_agent,903571-FS1,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
503669155,7/16/2014 21:59:15,,1324501488,7/16/2014 21:58:55,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[CAUSES],[CAUSES],VARIOLA VIRUS the cause of SMALLPOX,N/A,77,104,89,112,1,RO-has_causative_agent,903571-FS1,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
503669155,7/16/2014 22:07:52,,1324504476,7/16/2014 22:07:11,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[CAUSES],[CAUSES],the cause of,Na,77,104,89,112,1,RO-has_causative_agent,903571-FS1,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
503669155,7/16/2014 22:09:28,,1324504904,7/16/2014 22:08:53,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[CAUSES],[CAUSES],the cause of,na,77,104,89,112,1,RO-has_causative_agent,903571-FS1,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
503669155,7/16/2014 22:13:25,,1324506335,7/16/2014 22:12:56,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],VARIOLA VIRUS the cause of SMALLPOX,N/A,77,104,89,112,1,RO-has_causative_agent,903571-FS1,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
503669155,7/16/2014 22:37:57,,1324516820,7/16/2014 22:37:23,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[CAUSES],[CAUSES],cause,n/a,77,104,89,112,1,RO-has_causative_agent,903571-FS1,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
503669155,7/16/2014 22:49:09,,1324520915,7/16/2014 22:48:52,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[PART_OF],[PART_OF],is the closest known,N/A,77,104,89,112,1,RO-has_causative_agent,903571-FS1,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
503669155,7/16/2014 22:56:11,,1324523926,7/16/2014 22:55:43,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES],[CAUSES],the cause,N/A,77,104,89,112,1,RO-has_causative_agent,903571-FS1,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
503669156,7/16/2014 21:20:17,,1324485987,7/16/2014 21:19:57,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treated,N/A,56,128,72,139,1,RO-may_treat,908106-FS1,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
503669156,7/16/2014 21:27:28,,1324489136,7/16/2014 21:27:11,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],have been treated with,N/A,56,128,72,139,1,RO-may_treat,908106-FS1,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
503669156,7/16/2014 21:30:27,,1324490318,7/16/2014 21:29:30,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],have been treated with,N/A,56,128,72,139,1,RO-may_treat,908106-FS1,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
503669156,7/16/2014 21:31:01,,1324490517,7/16/2014 21:30:27,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],have been treated with the,N/A,56,128,72,139,1,RO-may_treat,908106-FS1,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
503669156,7/16/2014 21:43:39,,1324495457,7/16/2014 21:43:18,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[TREATS],[TREATS],HODGKIN'S DISEASE treated with VINCRISTINE,N/A,56,128,72,139,1,RO-may_treat,908106-FS1,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
503669156,7/16/2014 21:52:47,,1324499128,7/16/2014 21:52:20,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[TREATS],[TREATS],treated with,[TREATS],56,128,72,139,1,RO-may_treat,908106-FS1,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
503669156,7/16/2014 21:59:30,,1324501571,7/16/2014 21:59:16,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],HODGKIN'S DISEASE have been treated with VINCRISTINE,N/A,56,128,72,139,1,RO-may_treat,908106-FS1,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
503669156,7/16/2014 22:03:10,,1324502973,7/16/2014 22:02:45,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[TREATS],[TREATS],treated with,na,56,128,72,139,1,RO-may_treat,908106-FS1,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
503669156,7/16/2014 22:21:22,,1324509751,7/16/2014 22:21:06,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[TREATS],[TREATS],HODGKIN'S DISEASE have been treated with the MOPP/ABV VINCRISTINE,N/A,56,128,72,139,1,RO-may_treat,908106-FS1,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
503669156,7/16/2014 22:49:43,,1324521144,7/16/2014 22:49:32,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treated,N/A,56,128,72,139,1,RO-may_treat,908106-FS1,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
503669156,7/16/2014 22:53:01,,1324522486,7/16/2014 22:52:29,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],have been treated,N/A,56,128,72,139,1,RO-may_treat,908106-FS1,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
503669156,7/16/2014 23:10:49,,1324528980,7/16/2014 23:10:38,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[TREATS],[TREATS],treated,N/A,56,128,72,139,1,RO-may_treat,908106-FS1,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
503669156,7/16/2014 23:19:39,,1324532722,7/16/2014 23:19:09,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],HODGKIN'S DISEASE been treated with VINCRISTINE,N/A,56,128,72,139,1,RO-may_treat,908106-FS1,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
503669156,7/16/2014 23:20:08,,1324533026,7/16/2014 23:19:54,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[TREATS],[TREATS],have been treated with,N/A,56,128,72,139,1,RO-may_treat,908106-FS1,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
503669156,7/16/2014 23:23:03,,1324534546,7/16/2014 23:22:35,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],have been treated with the,na,56,128,72,139,1,RO-may_treat,908106-FS1,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
503669157,7/16/2014 21:19:51,,1324485787,7/16/2014 21:19:41,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],in the treatment of,N/A,53,11,67,32,1,RO-may_treat,907897-FS1,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
503669157,7/16/2014 21:23:08,,1324487113,7/16/2014 21:22:53,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[TREATS],[TREATS],treatment,N/A,53,11,67,32,1,RO-may_treat,907897-FS1,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
503669157,7/16/2014 21:23:35,,1324487340,7/16/2014 21:23:17,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treatment,N/A,53,11,67,32,1,RO-may_treat,907897-FS1,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
503669157,7/16/2014 21:34:12,,1324491779,7/16/2014 21:33:48,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],use of,N/A,53,11,67,32,1,RO-may_treat,907897-FS1,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
503669157,7/16/2014 21:39:07,,1324493597,7/16/2014 21:38:55,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],treatment,N/A,53,11,67,32,1,RO-may_treat,907897-FS1,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
503669157,7/16/2014 21:54:12,,1324499691,7/16/2014 21:53:56,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,N/A,53,11,67,32,1,RO-may_treat,907897-FS1,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
503669157,7/16/2014 21:56:00,,1324500343,7/16/2014 21:55:35,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],INSULIN SECRETAGOGUES treatment TYPE 2 DIABETES,n/a,53,11,67,32,1,RO-may_treat,907897-FS1,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
503669157,7/16/2014 22:27:29,,1324512200,7/16/2014 22:27:00,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[TREATS],[TREATS],INSULIN SECRETAGOGUES in treatment of TYPE DIABETES,N/A,53,11,67,32,1,RO-may_treat,907897-FS1,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
503669157,7/16/2014 22:39:06,,1324517241,7/16/2014 22:38:54,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],treatment,n/a,53,11,67,32,1,RO-may_treat,907897-FS1,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
503669157,7/16/2014 23:10:23,,1324528788,7/16/2014 23:08:52,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treatment,N/A,53,11,67,32,1,RO-may_treat,907897-FS1,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
503669157,7/16/2014 23:13:36,,1324530127,7/16/2014 23:13:23,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[TREATS],[TREATS],treatment,N/A,53,11,67,32,1,RO-may_treat,907897-FS1,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
503669157,7/16/2014 23:19:03,,1324532390,7/16/2014 23:17:54,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[TREATS],[TREATS],use of in the treatment of,N/A,53,11,67,32,1,RO-may_treat,907897-FS1,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
503669157,7/16/2014 23:22:35,,1324534301,7/16/2014 23:22:16,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],in the treatment of,na,53,11,67,32,1,RO-may_treat,907897-FS1,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
503669157,7/16/2014 23:23:04,,1324534547,7/16/2014 23:22:46,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],INSULIN SECRETAGOGUES treatment of TYPE 2 DIABETES,N/A,53,11,67,32,1,RO-may_treat,907897-FS1,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
503669157,7/16/2014 23:28:04,,1324536770,7/16/2014 23:27:42,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],in the treatment of,n/a,53,11,67,32,1,RO-may_treat,907897-FS1,The use of INSULIN SECRETAGOGUES in the treatment of TYPE 2 DIABETES,TYPE 2 DIABETES,INSULIN SECRETAGOGUES
503669158,7/16/2014 21:19:08,,1324485506,7/16/2014 21:18:49,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],for,N/A,92,69,120,87,1,RO-may_treat,907579-FS1,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
503669158,7/16/2014 21:21:05,,1324486278,7/16/2014 21:20:51,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],for,N/A,92,69,120,87,1,RO-may_treat,907579-FS1,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
503669158,7/16/2014 21:25:41,,1324488339,7/16/2014 21:25:29,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA,N/A,92,69,120,87,1,RO-may_treat,907579-FS1,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
503669158,7/16/2014 21:27:15,,1324489051,7/16/2014 21:27:00,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[TREATS],[TREATS],for,N/A,92,69,120,87,1,RO-may_treat,907579-FS1,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
503669158,7/16/2014 21:30:00,,1324490196,7/16/2014 21:29:47,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[MANIFESTATION],[MANIFESTATION],"GK, RN",asd,92,69,120,87,1,RO-may_treat,907579-FS1,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
503669158,7/16/2014 21:30:30,,1324490348,7/16/2014 21:30:14,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],for,N/A,92,69,120,87,1,RO-may_treat,907579-FS1,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
503669158,7/16/2014 21:33:47,,1324491613,7/16/2014 21:32:42,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],following,N/A,92,69,120,87,1,RO-may_treat,907579-FS1,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
503669158,7/16/2014 21:36:51,,1324492833,7/16/2014 21:36:39,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],for,N/A,92,69,120,87,1,RO-may_treat,907579-FS1,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
503669158,7/16/2014 21:41:54,,1324494718,7/16/2014 21:41:23,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[ASSOCIATED_WITH] [TREATS],"[TREATS]
[ASSOCIATED_WITH]",for,[ASSOCIATED_WITH] [TREATS],92,69,120,87,1,RO-may_treat,907579-FS1,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
503669158,7/16/2014 21:51:02,,1324498351,7/16/2014 21:50:47,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],THERAPY,n/a,92,69,120,87,1,RO-may_treat,907579-FS1,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
503669158,7/16/2014 21:59:53,,1324501719,7/16/2014 21:59:31,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[TREATS],[TREATS],INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA,N/A,92,69,120,87,1,RO-may_treat,907579-FS1,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
503669158,7/16/2014 22:01:56,,1324502442,7/16/2014 22:01:21,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[TREATS],[TREATS],THERAPY for,na,92,69,120,87,1,RO-may_treat,907579-FS1,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
503669158,7/16/2014 22:12:53,,1324506121,7/16/2014 22:12:01,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA,n/a,92,69,120,87,1,RO-may_treat,907579-FS1,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
503669158,7/16/2014 22:17:36,,1324508055,7/16/2014 22:16:50,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[ASSOCIATED_WITH],[ASSOCIATED_WITH],INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA,N/A,92,69,120,87,1,RO-may_treat,907579-FS1,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
503669158,7/16/2014 22:36:41,,1324516174,7/16/2014 22:35:24,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],for,n/a,92,69,120,87,1,RO-may_treat,907579-FS1,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
503669159,7/16/2014 21:20:55,,1324486217,7/16/2014 21:20:39,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[CAUSES],[CAUSES],main culprit,N/A,163,75,181,94,-1,RO-has_manifestation,906446-FS1,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
503669159,7/16/2014 21:21:06,,1324486287,7/16/2014 21:20:41,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],is considered the main culprit,N/A,163,75,181,94,-1,RO-has_manifestation,906446-FS1,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
503669159,7/16/2014 21:22:39,,1324486931,7/16/2014 21:21:24,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],induced,N/A,163,75,181,94,-1,RO-has_manifestation,906446-FS1,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
503669159,7/16/2014 21:26:57,,1324488915,7/16/2014 21:26:29,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],considered,N/A,163,75,181,94,-1,RO-has_manifestation,906446-FS1,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
503669159,7/16/2014 21:30:44,,1324490427,7/16/2014 21:30:28,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],considered the main culprit,N/A,163,75,181,94,-1,RO-has_manifestation,906446-FS1,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
503669159,7/16/2014 21:32:46,,1324491173,7/16/2014 21:32:24,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],main culprit,N/A,163,75,181,94,-1,RO-has_manifestation,906446-FS1,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
503669159,7/16/2014 21:33:52,,1324491635,7/16/2014 21:32:59,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],considered the main culprit in,N/A,163,75,181,94,-1,RO-has_manifestation,906446-FS1,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
503669159,7/16/2014 21:56:25,,1324500521,7/16/2014 21:55:34,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[IS_A],[IS_A],is considered the main culprit,[IS_A],163,75,181,94,-1,RO-has_manifestation,906446-FS1,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
503669159,7/16/2014 22:22:42,,1324510255,7/16/2014 22:22:10,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[CAUSES],[CAUSES],culprit,na,163,75,181,94,-1,RO-has_manifestation,906446-FS1,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
503669159,7/16/2014 22:44:47,,1324519225,7/16/2014 22:44:19,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[CAUSES],[CAUSES],is considered the main culprit,N/A,163,75,181,94,-1,RO-has_manifestation,906446-FS1,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
503669159,7/16/2014 23:00:43,,1324525411,7/16/2014 23:00:09,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES],[CAUSES],considered the main culprit,N/A,163,75,181,94,-1,RO-has_manifestation,906446-FS1,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
503669159,7/16/2014 23:11:32,,1324529246,7/16/2014 23:11:18,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],known as,N/A,163,75,181,94,-1,RO-has_manifestation,906446-FS1,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
503669159,7/16/2014 23:16:15,,1324531094,7/16/2014 23:15:44,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[CAUSES],[CAUSES],is considered the main culprit in drug induced arrhythmias known as,N/A,163,75,181,94,-1,RO-has_manifestation,906446-FS1,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
503669159,7/16/2014 23:20:21,,1324533123,7/16/2014 23:18:19,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],considered the main culprit,N/A,163,75,181,94,-1,RO-has_manifestation,906446-FS1,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
503669159,7/16/2014 23:22:16,,1324534144,7/16/2014 23:21:29,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],is considered the main culprit in drug induced arrhythmias known as,na,163,75,181,94,-1,RO-has_manifestation,906446-FS1,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
503669160,7/16/2014 21:22:03,,1324486669,7/16/2014 21:21:34,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[OTHER],[OTHER],in FLUORIDE DEFICIENT AREAS.,N/A,170,96,193,112,-1,RO-has_causative_agent,903698-FS1,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
503669160,7/16/2014 21:22:25,,1324486823,7/16/2014 21:22:12,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],both and,N/A,170,96,193,112,-1,RO-has_causative_agent,903698-FS1,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
503669160,7/16/2014 21:28:35,,1324489530,7/16/2014 21:28:00,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],have increased,N/A,170,96,193,112,-1,RO-has_causative_agent,903698-FS1,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
503669160,7/16/2014 21:29:50,,1324490131,7/16/2014 21:29:12,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],have increased,N/A,170,96,193,112,-1,RO-has_causative_agent,903698-FS1,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
503669160,7/16/2014 21:32:23,,1324491028,7/16/2014 21:31:48,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],have increased in,N/A,170,96,193,112,-1,RO-has_causative_agent,903698-FS1,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
503669160,7/16/2014 21:32:50,,1324491185,7/16/2014 21:32:20,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],have increased in schoolchildren in both fluoridated and,N/A,170,96,193,112,-1,RO-has_causative_agent,903698-FS1,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
503669160,7/16/2014 21:38:11,,1324493248,7/16/2014 21:37:55,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],increased in,N/A,170,96,193,112,-1,RO-has_causative_agent,903698-FS1,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
503669160,7/16/2014 21:40:04,,1324494026,7/16/2014 21:39:23,clixsense,1.0,15189335,GBR,H9,London,188.29.165.50,[CAUSES],[CAUSES],have increased,Na,170,96,193,112,-1,RO-has_causative_agent,903698-FS1,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
503669160,7/16/2014 21:47:07,,1324496908,7/16/2014 21:46:45,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[CAUSES],[CAUSES],DENTAL FLUOROSIS have increased in FLUORIDE DEFICIENT AREAS.,N/A,170,96,193,112,-1,RO-has_causative_agent,903698-FS1,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
503669160,7/16/2014 21:55:32,,1324500211,7/16/2014 21:54:58,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],have increased in,[DIAGNOSE_BY_TEST_OR_DRUG],170,96,193,112,-1,RO-has_causative_agent,903698-FS1,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
503669160,7/16/2014 22:05:14,,1324503672,7/16/2014 22:04:31,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[MANIFESTATION],[MANIFESTATION],the intensity of DENTAL FLUOROSIS have increased in both fluoridated and FLUORIDE DEFICIENT AREAS.,N/A,170,96,193,112,-1,RO-has_causative_agent,903698-FS1,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
503669160,7/16/2014 22:15:55,,1324507337,7/16/2014 22:14:36,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],intensity of DENTAL FLUOROSIS have increased in FLUORIDE DEFICIENT AREAS.,N/A,170,96,193,112,-1,RO-has_causative_agent,903698-FS1,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
503669160,7/16/2014 22:59:31,,1324525041,7/16/2014 22:59:09,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"Recent studies indicate,",N/A,170,96,193,112,-1,RO-has_causative_agent,903698-FS1,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
503669160,7/16/2014 23:12:32,,1324529682,7/16/2014 23:12:16,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],have increased in schoolchildren,N/A,170,96,193,112,-1,RO-has_causative_agent,903698-FS1,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
503669160,7/16/2014 23:17:35,,1324531690,7/16/2014 23:16:16,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[ASSOCIATED_WITH],[ASSOCIATED_WITH],have increased in schoolchildren in both,N/A,170,96,193,112,-1,RO-has_causative_agent,903698-FS1,"Recent studies indicate, however, that the prevalence and, to a lesser extent, the intensity of DENTAL FLUOROSIS have increased in schoolchildren in both fluoridated and FLUORIDE DEFICIENT AREAS.",FLUORIDE DEFICIENT AREAS,DENTAL FLUOROSIS
503669161,7/16/2014 21:24:32,,1324487818,7/16/2014 21:24:09,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],Treatment,N/A,84,13,90,23,1,RO-has_causative_agent,903897-FS1,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
503669161,7/16/2014 21:27:48,,1324489243,7/16/2014 21:27:40,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],Treatment of,N/A,84,13,90,23,1,RO-has_causative_agent,903897-FS1,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
503669161,7/16/2014 21:32:19,,1324491017,7/16/2014 21:31:53,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],because of the changing epidemiology of,N/A,84,13,90,23,1,RO-has_causative_agent,903897-FS1,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
503669161,7/16/2014 21:34:14,,1324491801,7/16/2014 21:33:56,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[MANIFESTATION],[MANIFESTATION],epidemiology,N/A,84,13,90,23,1,RO-has_causative_agent,903897-FS1,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
503669161,7/16/2014 21:36:27,,1324492689,7/16/2014 21:35:37,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],is complicated,N/A,84,13,90,23,1,RO-has_causative_agent,903897-FS1,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
503669161,7/16/2014 21:45:27,,1324496234,7/16/2014 21:45:03,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[OTHER],[OTHER],CANDIDEMIA because of CANDIDA,The relation is not clear in this extract,84,13,90,23,1,RO-has_causative_agent,903897-FS1,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
503669161,7/16/2014 21:58:09,,1324501122,7/16/2014 21:57:41,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[MANIFESTATION],[MANIFESTATION],more complicated because of the changing epidemiology,N/A,84,13,90,23,1,RO-has_causative_agent,903897-FS1,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
503669161,7/16/2014 21:58:20,,1324501172,7/16/2014 21:57:34,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],CANDIDEMIA epidemiology CANDIDA,n/a,84,13,90,23,1,RO-has_causative_agent,903897-FS1,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
503669161,7/16/2014 22:02:17,,1324502598,7/16/2014 22:01:48,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA,N/A,84,13,90,23,1,RO-has_causative_agent,903897-FS1,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
503669161,7/16/2014 22:03:22,,1324503040,7/16/2014 22:02:40,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[CAUSES],[CAUSES],changing epidemiology of,Na,84,13,90,23,1,RO-has_causative_agent,903897-FS1,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
503669161,7/16/2014 22:32:38,,1324514286,7/16/2014 22:30:52,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[ASSOCIATED_WITH] [PART_OF] [IS_A],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",CANDIDEMIA more complicated because epidemiology of CANDIDA,N/A,84,13,90,23,1,RO-has_causative_agent,903897-FS1,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
503669161,7/16/2014 22:33:50,,1324514759,7/16/2014 22:33:08,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],changing epidemiology,n/a,84,13,90,23,1,RO-has_causative_agent,903897-FS1,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
503669161,7/16/2014 22:50:23,,1324521345,7/16/2014 22:50:06,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],Treatment,N/A,84,13,90,23,1,RO-has_causative_agent,903897-FS1,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
503669161,7/16/2014 23:15:37,,1324530840,7/16/2014 23:15:23,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[IS_A],[IS_A],CANDIDA,N/A,84,13,90,23,1,RO-has_causative_agent,903897-FS1,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
503669161,7/16/2014 23:19:08,,1324532427,7/16/2014 23:18:42,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],CANDIDEMIA because of epidemiology of CANDIDA,N/A,84,13,90,23,1,RO-has_causative_agent,903897-FS1,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
503669162,7/16/2014 21:24:07,,1324487637,7/16/2014 21:23:35,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],established,N/A,169,122,196,132,-1,RO-has_causative_agent,903974-FS1,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with ASBESTOSIS in comparison with those exposed to ASBESTOS ASSOCIATED FIBROSIS were studied in 110 patients.,ASBESTOS ASSOCIATED FIBROSIS,ASBESTOSIS
503669162,7/16/2014 21:25:29,,1324488229,7/16/2014 21:24:54,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASBESTOSIS ASBESTOS,N/A,169,122,196,132,-1,RO-has_causative_agent,903974-FS1,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with ASBESTOSIS in comparison with those exposed to ASBESTOS ASSOCIATED FIBROSIS were studied in 110 patients.,ASBESTOS ASSOCIATED FIBROSIS,ASBESTOSIS
503669162,7/16/2014 21:30:02,,1324490199,7/16/2014 21:29:28,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],in comparison with those exposed to,N/A,169,122,196,132,-1,RO-has_causative_agent,903974-FS1,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with ASBESTOSIS in comparison with those exposed to ASBESTOS ASSOCIATED FIBROSIS were studied in 110 patients.,ASBESTOS ASSOCIATED FIBROSIS,ASBESTOSIS
503669162,7/16/2014 21:34:45,,1324491966,7/16/2014 21:34:26,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CAUSES],[CAUSES],exposed,N/A,169,122,196,132,-1,RO-has_causative_agent,903974-FS1,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with ASBESTOSIS in comparison with those exposed to ASBESTOS ASSOCIATED FIBROSIS were studied in 110 patients.,ASBESTOS ASSOCIATED FIBROSIS,ASBESTOSIS
503669162,7/16/2014 21:37:13,,1324492934,7/16/2014 21:36:28,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],exposed to,N/A,169,122,196,132,-1,RO-has_causative_agent,903974-FS1,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with ASBESTOSIS in comparison with those exposed to ASBESTOS ASSOCIATED FIBROSIS were studied in 110 patients.,ASBESTOS ASSOCIATED FIBROSIS,ASBESTOSIS
503669162,7/16/2014 21:43:18,,1324495306,7/16/2014 21:42:14,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[OTHER],[OTHER],in comparison with,different conditions,169,122,196,132,-1,RO-has_causative_agent,903974-FS1,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with ASBESTOSIS in comparison with those exposed to ASBESTOS ASSOCIATED FIBROSIS were studied in 110 patients.,ASBESTOS ASSOCIATED FIBROSIS,ASBESTOSIS
503669162,7/16/2014 21:59:47,,1324501668,7/16/2014 21:58:20,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH] [OTHER],"[ASSOCIATED_WITH]
[OTHER]",ASBESTOSIS in comparison ASBESTOS ASSOCIATED FIBROSIS,In Comparison,169,122,196,132,-1,RO-has_causative_agent,903974-FS1,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with ASBESTOSIS in comparison with those exposed to ASBESTOS ASSOCIATED FIBROSIS were studied in 110 patients.,ASBESTOS ASSOCIATED FIBROSIS,ASBESTOSIS
503669162,7/16/2014 22:04:10,,1324503340,7/16/2014 22:03:38,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH] [OTHER],"[ASSOCIATED_WITH]
[OTHER]",in comparison with those exposed,N/A,169,122,196,132,-1,RO-has_causative_agent,903974-FS1,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with ASBESTOSIS in comparison with those exposed to ASBESTOS ASSOCIATED FIBROSIS were studied in 110 patients.,ASBESTOS ASSOCIATED FIBROSIS,ASBESTOSIS
503669162,7/16/2014 22:10:53,,1324505418,7/16/2014 22:10:21,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in comparison,Na,169,122,196,132,-1,RO-has_causative_agent,903974-FS1,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with ASBESTOSIS in comparison with those exposed to ASBESTOS ASSOCIATED FIBROSIS were studied in 110 patients.,ASBESTOS ASSOCIATED FIBROSIS,ASBESTOSIS
503669162,7/16/2014 22:21:00,,1324509575,7/16/2014 22:20:35,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASSOCIATED,na,169,122,196,132,-1,RO-has_causative_agent,903974-FS1,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with ASBESTOSIS in comparison with those exposed to ASBESTOS ASSOCIATED FIBROSIS were studied in 110 patients.,ASBESTOS ASSOCIATED FIBROSIS,ASBESTOSIS
503669162,7/16/2014 22:24:09,,1324510770,7/16/2014 22:23:42,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASBESTOSIS in comparison with those exposed to ASBESTOS ASSOCIATED FIBROSIS,N/A,169,122,196,132,-1,RO-has_causative_agent,903974-FS1,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with ASBESTOSIS in comparison with those exposed to ASBESTOS ASSOCIATED FIBROSIS were studied in 110 patients.,ASBESTOS ASSOCIATED FIBROSIS,ASBESTOSIS
503669162,7/16/2014 22:38:27,,1324516991,7/16/2014 22:37:59,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],in comparison,n/a,169,122,196,132,-1,RO-has_causative_agent,903974-FS1,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with ASBESTOSIS in comparison with those exposed to ASBESTOS ASSOCIATED FIBROSIS were studied in 110 patients.,ASBESTOS ASSOCIATED FIBROSIS,ASBESTOSIS
503669162,7/16/2014 23:06:17,,1324527433,7/16/2014 23:05:32,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],comparison with,N/A,169,122,196,132,-1,RO-has_causative_agent,903974-FS1,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with ASBESTOSIS in comparison with those exposed to ASBESTOS ASSOCIATED FIBROSIS were studied in 110 patients.,ASBESTOS ASSOCIATED FIBROSIS,ASBESTOSIS
503669162,7/16/2014 23:10:38,,1324528884,7/16/2014 23:10:19,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,list,169,122,196,132,-1,RO-has_causative_agent,903974-FS1,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with ASBESTOSIS in comparison with those exposed to ASBESTOS ASSOCIATED FIBROSIS were studied in 110 patients.,ASBESTOS ASSOCIATED FIBROSIS,ASBESTOSIS
503669162,7/16/2014 23:14:54,,1324530550,7/16/2014 23:14:23,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[NONE],[NONE],N/A,two dif diseases,169,122,196,132,-1,RO-has_causative_agent,903974-FS1,Proceesing from the epidemiologic survey higher risk of malignant neoplasms of the lungs was established in patients with ASBESTOSIS in comparison with those exposed to ASBESTOS ASSOCIATED FIBROSIS were studied in 110 patients.,ASBESTOS ASSOCIATED FIBROSIS,ASBESTOSIS
503669163,7/16/2014 21:19:44,,1324485721,7/16/2014 21:19:34,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],them exhibiting marked,N/A,17,64,32,86,-1,RO-has_manifestation,906208-FS1,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
503669163,7/16/2014 21:21:33,,1324486418,7/16/2014 21:21:18,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[PART_OF],[PART_OF],exhibiting marked,N/A,17,64,32,86,-1,RO-has_manifestation,906208-FS1,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
503669163,7/16/2014 21:22:55,,1324487033,7/16/2014 21:22:30,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],exhibiting,N/A,17,64,32,86,-1,RO-has_manifestation,906208-FS1,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
503669163,7/16/2014 21:27:03,,1324488964,7/16/2014 21:26:34,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],exhibiting,N/A,17,64,32,86,-1,RO-has_manifestation,906208-FS1,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
503669163,7/16/2014 21:30:08,,1324490246,7/16/2014 21:29:50,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],exhibiting marked,N/A,17,64,32,86,-1,RO-has_manifestation,906208-FS1,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
503669163,7/16/2014 21:33:13,,1324491253,7/16/2014 21:32:52,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],one of them exhibiting marked,N/A,17,64,32,86,-1,RO-has_manifestation,906208-FS1,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
503669163,7/16/2014 21:39:38,,1324493846,7/16/2014 21:39:08,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SYMPTOM],[SYMPTOM],marked,N/A,17,64,32,86,-1,RO-has_manifestation,906208-FS1,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
503669163,7/16/2014 21:45:02,,1324496027,7/16/2014 21:44:44,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[NONE],[NONE],N/A,Different conditions / results,17,64,32,86,-1,RO-has_manifestation,906208-FS1,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
503669163,7/16/2014 22:00:02,,1324501749,7/16/2014 21:59:32,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[IS_A],[IS_A],one of them,N/A,17,64,32,86,-1,RO-has_manifestation,906208-FS1,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
503669163,7/16/2014 22:00:05,,1324501756,7/16/2014 21:59:32,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[CAUSES] [MANIFESTATION] [SYMPTOM],"[CAUSES]
[SYMPTOM]
[MANIFESTATION]",All cases showed exhibiting marked,[CAUSES] [MANIFESTATION] [SYMPTOM],17,64,32,86,-1,RO-has_manifestation,906208-FS1,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
503669163,7/16/2014 22:07:33,,1324504382,7/16/2014 22:07:01,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]",showed FACIAL ASYMMETRY marked FACIAL HEMIHYPERTROPHY,n/a,17,64,32,86,-1,RO-has_manifestation,906208-FS1,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
503669163,7/16/2014 22:08:33,,1324504659,7/16/2014 22:07:53,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",All cases showed,Na,17,64,32,86,-1,RO-has_manifestation,906208-FS1,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
503669163,7/16/2014 22:23:02,,1324510391,7/16/2014 22:22:48,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,N/A,17,64,32,86,-1,RO-has_manifestation,906208-FS1,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
503669163,7/16/2014 22:42:57,,1324518614,7/16/2014 22:42:00,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],one of them exhibiting,n/a,17,64,32,86,-1,RO-has_manifestation,906208-FS1,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
503669163,7/16/2014 23:06:53,,1324527629,7/16/2014 23:06:19,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",exhibiting marked,N/A,17,64,32,86,-1,RO-has_manifestation,906208-FS1,All cases showed FACIAL ASYMMETRY one of them exhibiting marked FACIAL HEMIHYPERTROPHY,FACIAL ASYMMETRY,FACIAL HEMIHYPERTROPHY
503669164,7/16/2014 21:21:17,,1324486334,7/16/2014 21:20:56,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[SYMPTOM],[SYMPTOM],show,N/A,90,49,109,62,1,RO-disease_has_finding,901798-FS1,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
503669164,7/16/2014 21:21:29,,1324486408,7/16/2014 21:21:06,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],show a higher frequency of,N/A,90,49,109,62,1,RO-disease_has_finding,901798-FS1,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
503669164,7/16/2014 21:30:26,,1324490312,7/16/2014 21:30:09,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],higher frequency,N/A,90,49,109,62,1,RO-disease_has_finding,901798-FS1,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
503669164,7/16/2014 21:30:46,,1324490433,7/16/2014 21:30:31,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Compared,N/A,90,49,109,62,1,RO-disease_has_finding,901798-FS1,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
503669164,7/16/2014 21:46:44,,1324496774,7/16/2014 21:46:23,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[CAUSES],[CAUSES],FLAT ADENOMAS show higher frequency of HIGH GRADE DYSPLASIA,N/A,90,49,109,62,1,RO-disease_has_finding,901798-FS1,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
503669164,7/16/2014 21:54:56,,1324500005,7/16/2014 21:54:22,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[MANIFESTATION],[MANIFESTATION],show a higher frequency of,[MANIFESTATION],90,49,109,62,1,RO-disease_has_finding,901798-FS1,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
503669164,7/16/2014 22:02:43,,1324502789,7/16/2014 22:02:21,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",show higher frequency of,N/A,90,49,109,62,1,RO-disease_has_finding,901798-FS1,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
503669164,7/16/2014 22:04:44,,1324503516,7/16/2014 22:04:20,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[MANIFESTATION],[MANIFESTATION],FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA,N/A,90,49,109,62,1,RO-disease_has_finding,901798-FS1,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
503669164,7/16/2014 22:10:29,,1324505293,7/16/2014 22:09:32,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],FLAT ADENOMAS HIGH GRADE DYSPLASIA,n/a,90,49,109,62,1,RO-disease_has_finding,901798-FS1,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
503669164,7/16/2014 22:13:13,,1324506230,7/16/2014 22:12:31,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",show higher frequency,Na,90,49,109,62,1,RO-disease_has_finding,901798-FS1,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
503669164,7/16/2014 22:14:27,,1324506795,7/16/2014 22:13:05,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[MANIFESTATION],[MANIFESTATION],FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA,N/A,90,49,109,62,1,RO-disease_has_finding,901798-FS1,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
503669164,7/16/2014 22:15:39,,1324507205,7/16/2014 22:15:03,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[MANIFESTATION],[MANIFESTATION],show a higher frequency of,na,90,49,109,62,1,RO-disease_has_finding,901798-FS1,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
503669164,7/16/2014 22:48:26,,1324520728,7/16/2014 22:48:05,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[SIDE_EFFECT],[SIDE_EFFECT],show,N/A,90,49,109,62,1,RO-disease_has_finding,901798-FS1,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
503669164,7/16/2014 23:11:04,,1324529034,7/16/2014 23:10:51,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[SYMPTOM],[SYMPTOM],higher frequency,N/A,90,49,109,62,1,RO-disease_has_finding,901798-FS1,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
503669164,7/16/2014 23:19:11,,1324532453,7/16/2014 23:18:06,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[SYMPTOM],[SYMPTOM],show a higher frequency of,na,90,49,109,62,1,RO-disease_has_finding,901798-FS1,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
503669165,7/16/2014 21:19:21,,1324485570,7/16/2014 21:19:00,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the same time marker,N/A,298,203,327,240,-1,RO-disease_has_finding,901838-FS1,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
503669165,7/16/2014 21:21:59,,1324486626,7/16/2014 21:21:06,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],expresses at the same time marker substances of,N/A,298,203,327,240,-1,RO-disease_has_finding,901838-FS1,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
503669165,7/16/2014 21:24:26,,1324487795,7/16/2014 21:23:45,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],marker substances,N/A,298,203,327,240,-1,RO-disease_has_finding,901838-FS1,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
503669165,7/16/2014 21:24:45,,1324487925,7/16/2014 21:24:07,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[ASSOCIATED_WITH],[ASSOCIATED_WITH],since it expresses at the same time marker substances of,N/A,298,203,327,240,-1,RO-disease_has_finding,901838-FS1,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
503669165,7/16/2014 21:24:49,,1324487934,7/16/2014 21:24:02,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],use in,N/A,298,203,327,240,-1,RO-disease_has_finding,901838-FS1,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
503669165,7/16/2014 21:26:20,,1324488619,7/16/2014 21:25:59,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[ASSOCIATED_WITH],[ASSOCIATED_WITH],expresses at the same time,N/A,298,203,327,240,-1,RO-disease_has_finding,901838-FS1,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
503669165,7/16/2014 21:27:20,,1324489090,7/16/2014 21:26:58,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],derived,N/A,298,203,327,240,-1,RO-disease_has_finding,901838-FS1,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
503669165,7/16/2014 21:31:05,,1324490535,7/16/2014 21:30:41,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],expresses,N/A,298,203,327,240,-1,RO-disease_has_finding,901838-FS1,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
503669165,7/16/2014 21:33:46,,1324491607,7/16/2014 21:33:03,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SIDE_EFFECT],[SIDE_EFFECT],NEUROENDOCRINE DIFFERENTIATION,asd,298,203,327,240,-1,RO-disease_has_finding,901838-FS1,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
503669165,7/16/2014 21:42:50,,1324495093,7/16/2014 21:42:09,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[OTHER],[OTHER],LARGE CELL TYPE NEUROENDOCRINE TUMORS NEUROENDOCRINE DIFFERENTIATION,The relation is not clear in this extract,298,203,327,240,-1,RO-disease_has_finding,901838-FS1,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
503669165,7/16/2014 21:50:23,,1324498126,7/16/2014 21:49:17,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",since it expresses at the same time,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],298,203,327,240,-1,RO-disease_has_finding,901838-FS1,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
503669165,7/16/2014 21:55:33,,1324500212,7/16/2014 21:52:51,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LARGE CELL TYPE NEUROENDOCRINE marker substances NEUROENDOCRINE DIFFERENTIATION,n/a,298,203,327,240,-1,RO-disease_has_finding,901838-FS1,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
503669165,7/16/2014 21:56:31,,1324500554,7/16/2014 21:55:56,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",since expresses at the same time marker,N/A,298,203,327,240,-1,RO-disease_has_finding,901838-FS1,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
503669165,7/16/2014 22:03:10,,1324502974,7/16/2014 22:02:38,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION,N/A,298,203,327,240,-1,RO-disease_has_finding,901838-FS1,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
503669165,7/16/2014 22:11:57,,1324505767,7/16/2014 22:11:23,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[ASSOCIATED_WITH],[ASSOCIATED_WITH],same time marker substances,Na,298,203,327,240,-1,RO-disease_has_finding,901838-FS1,KTA7 was considered to be derived from large cell undifferentiated carcinoma with neuroendocrine differentiation (large cell neuroendocrine tumor) and thus may fine use in studies on the pathobiology of LARGE CELL TYPE NEUROENDOCRINE TUMORS since it expresses at the same time marker substances of NEUROENDOCRINE DIFFERENTIATION and the hCG alpha subunit.,NEUROENDOCRINE DIFFERENTIATION,LARGE CELL TYPE NEUROENDOCRINE TUMORS
503669166,7/16/2014 21:28:36,,1324489537,7/16/2014 21:28:05,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASSOCIATIONS,N/A,13,53,24,62,-1,RO-cause_of,900309-FS1,The clinical ASSOCIATIONS of kiwi fruit allergy with ALLERGIES to pollens or latex are reviewed.,ASSOCIATIONS,ALLERGIES
503669166,7/16/2014 21:29:26,,1324489988,7/16/2014 21:29:14,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],ASSOCIATIONS,asd,13,53,24,62,-1,RO-cause_of,900309-FS1,The clinical ASSOCIATIONS of kiwi fruit allergy with ALLERGIES to pollens or latex are reviewed.,ASSOCIATIONS,ALLERGIES
503669166,7/16/2014 21:29:38,,1324490079,7/16/2014 21:29:08,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASSOCIATIONS,N/A,13,53,24,62,-1,RO-cause_of,900309-FS1,The clinical ASSOCIATIONS of kiwi fruit allergy with ALLERGIES to pollens or latex are reviewed.,ASSOCIATIONS,ALLERGIES
503669166,7/16/2014 21:38:21,,1324493326,7/16/2014 21:38:11,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASSOCIATIONS,N/A,13,53,24,62,-1,RO-cause_of,900309-FS1,The clinical ASSOCIATIONS of kiwi fruit allergy with ALLERGIES to pollens or latex are reviewed.,ASSOCIATIONS,ALLERGIES
503669166,7/16/2014 21:41:37,,1324494641,7/16/2014 21:41:05,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[OTHER],[OTHER],ASSOCIATIONS of kiwi with ALLERGIES,Associations needs full term,13,53,24,62,-1,RO-cause_of,900309-FS1,The clinical ASSOCIATIONS of kiwi fruit allergy with ALLERGIES to pollens or latex are reviewed.,ASSOCIATIONS,ALLERGIES
503669166,7/16/2014 21:50:46,,1324498237,7/16/2014 21:50:27,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASSOCIATIONS,n/a,13,53,24,62,-1,RO-cause_of,900309-FS1,The clinical ASSOCIATIONS of kiwi fruit allergy with ALLERGIES to pollens or latex are reviewed.,ASSOCIATIONS,ALLERGIES
503669166,7/16/2014 22:03:25,,1324503059,7/16/2014 22:03:11,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASSOCIATIONS of kiwi fruit allergy with ALLERGIES,N/A,13,53,24,62,-1,RO-cause_of,900309-FS1,The clinical ASSOCIATIONS of kiwi fruit allergy with ALLERGIES to pollens or latex are reviewed.,ASSOCIATIONS,ALLERGIES
503669166,7/16/2014 22:35:22,,1324515561,7/16/2014 22:34:43,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASSOCIATIONS,n/a,13,53,24,62,-1,RO-cause_of,900309-FS1,The clinical ASSOCIATIONS of kiwi fruit allergy with ALLERGIES to pollens or latex are reviewed.,ASSOCIATIONS,ALLERGIES
503669166,7/16/2014 22:47:47,,1324520530,7/16/2014 22:47:32,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,13,53,24,62,-1,RO-cause_of,900309-FS1,The clinical ASSOCIATIONS of kiwi fruit allergy with ALLERGIES to pollens or latex are reviewed.,ASSOCIATIONS,ALLERGIES
503669166,7/16/2014 23:05:02,,1324527001,7/16/2014 23:04:40,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],clinical ASSOCIATIONS,N/A,13,53,24,62,-1,RO-cause_of,900309-FS1,The clinical ASSOCIATIONS of kiwi fruit allergy with ALLERGIES to pollens or latex are reviewed.,ASSOCIATIONS,ALLERGIES
503669166,7/16/2014 23:14:40,,1324530488,7/16/2014 23:14:25,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASSOCIATIONS,N/A,13,53,24,62,-1,RO-cause_of,900309-FS1,The clinical ASSOCIATIONS of kiwi fruit allergy with ALLERGIES to pollens or latex are reviewed.,ASSOCIATIONS,ALLERGIES
503669166,7/16/2014 23:18:05,,1324531937,7/16/2014 23:16:53,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated terms,13,53,24,62,-1,RO-cause_of,900309-FS1,The clinical ASSOCIATIONS of kiwi fruit allergy with ALLERGIES to pollens or latex are reviewed.,ASSOCIATIONS,ALLERGIES
503669166,7/16/2014 23:22:17,,1324534165,7/16/2014 23:21:51,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[NONE],[NONE],N/A,totally unrelated,13,53,24,62,-1,RO-cause_of,900309-FS1,The clinical ASSOCIATIONS of kiwi fruit allergy with ALLERGIES to pollens or latex are reviewed.,ASSOCIATIONS,ALLERGIES
503669166,7/16/2014 23:22:45,,1324534394,7/16/2014 23:22:19,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],clinical ASSOCIATIONS of kiwi with ALLERGIES,N/A,13,53,24,62,-1,RO-cause_of,900309-FS1,The clinical ASSOCIATIONS of kiwi fruit allergy with ALLERGIES to pollens or latex are reviewed.,ASSOCIATIONS,ALLERGIES
503669166,7/16/2014 23:28:30,,1324537043,7/16/2014 23:28:04,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASSOCIATIONS of kiwi fruit allergy with,n/a,13,53,24,62,-1,RO-cause_of,900309-FS1,The clinical ASSOCIATIONS of kiwi fruit allergy with ALLERGIES to pollens or latex are reviewed.,ASSOCIATIONS,ALLERGIES
503669167,7/16/2014 21:19:55,,1324485848,7/16/2014 21:19:29,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,150,171,166,189,-1,RO-cause_of,900231-FS1,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
503669167,7/16/2014 21:20:38,,1324486082,7/16/2014 21:20:22,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,150,171,166,189,-1,RO-cause_of,900231-FS1,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
503669167,7/16/2014 21:26:05,,1324488505,7/16/2014 21:24:50,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[LOCATION],[LOCATION],was found,N/A,150,171,166,189,-1,RO-cause_of,900231-FS1,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
503669167,7/16/2014 21:27:09,,1324489011,7/16/2014 21:26:58,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,150,171,166,189,-1,RO-cause_of,900231-FS1,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
503669167,7/16/2014 21:29:43,,1324490092,7/16/2014 21:29:30,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[LOCATION],[LOCATION],hydrocortisone,asd,150,171,166,189,-1,RO-cause_of,900231-FS1,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
503669167,7/16/2014 21:30:20,,1324490281,7/16/2014 21:30:09,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,150,171,166,189,-1,RO-cause_of,900231-FS1,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
503669167,7/16/2014 21:31:48,,1324490808,7/16/2014 21:31:25,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients with or,N/A,150,171,166,189,-1,RO-cause_of,900231-FS1,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
503669167,7/16/2014 21:43:33,,1324495435,7/16/2014 21:42:30,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",was found to be,[LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG],150,171,166,189,-1,RO-cause_of,900231-FS1,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
503669167,7/16/2014 21:47:42,,1324497085,7/16/2014 21:45:26,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[IS_A],[IS_A],or,n/a,150,171,166,189,-1,RO-cause_of,900231-FS1,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
503669167,7/16/2014 22:11:59,,1324505769,7/16/2014 22:11:30,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with or,na,150,171,166,189,-1,RO-cause_of,900231-FS1,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
503669167,7/16/2014 22:12:29,,1324505930,7/16/2014 22:12:00,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",or,Na,150,171,166,189,-1,RO-cause_of,900231-FS1,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
503669167,7/16/2014 22:29:16,,1324513000,7/16/2014 22:28:45,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],or,n/a,150,171,166,189,-1,RO-cause_of,900231-FS1,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
503669167,7/16/2014 22:51:25,,1324521839,7/16/2014 22:50:43,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],in a double blind study,N/A,150,171,166,189,-1,RO-cause_of,900231-FS1,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
503669167,7/16/2014 23:15:09,,1324530637,7/16/2014 23:14:58,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,list,150,171,166,189,-1,RO-cause_of,900231-FS1,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
503669167,7/16/2014 23:20:27,,1324533167,7/16/2014 23:20:09,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[NONE],[NONE],N/A,two dif diseases,150,171,166,189,-1,RO-cause_of,900231-FS1,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
503669168,7/16/2014 21:20:13,,1324485974,7/16/2014 21:19:17,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],are combined,N/A,38,99,51,103,1,RO-disease_has_finding,901883-FS1,"Cellular changes consistent with HPV, MILD DYSPLASIA and CIN 1 are combined within the category of LSIL",MILD DYSPLASIA,LSIL
503669168,7/16/2014 21:28:02,,1324489315,7/16/2014 21:27:04,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],changes consistent with,N/A,38,99,51,103,1,RO-disease_has_finding,901883-FS1,"Cellular changes consistent with HPV, MILD DYSPLASIA and CIN 1 are combined within the category of LSIL",MILD DYSPLASIA,LSIL
503669168,7/16/2014 21:31:19,,1324490623,7/16/2014 21:31:06,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PART_OF],[PART_OF],within,N/A,38,99,51,103,1,RO-disease_has_finding,901883-FS1,"Cellular changes consistent with HPV, MILD DYSPLASIA and CIN 1 are combined within the category of LSIL",MILD DYSPLASIA,LSIL
503669168,7/16/2014 21:32:30,,1324491066,7/16/2014 21:32:19,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,38,99,51,103,1,RO-disease_has_finding,901883-FS1,"Cellular changes consistent with HPV, MILD DYSPLASIA and CIN 1 are combined within the category of LSIL",MILD DYSPLASIA,LSIL
503669168,7/16/2014 21:33:32,,1324491471,7/16/2014 21:32:03,clixsense,1.0,15189335,GBR,H9,London,188.29.164.50,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,38,99,51,103,1,RO-disease_has_finding,901883-FS1,"Cellular changes consistent with HPV, MILD DYSPLASIA and CIN 1 are combined within the category of LSIL",MILD DYSPLASIA,LSIL
503669168,7/16/2014 21:39:48,,1324493955,7/16/2014 21:39:28,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[IS_A],[IS_A],MILD DYSPLASIA within category of LSIL,N/A,38,99,51,103,1,RO-disease_has_finding,901883-FS1,"Cellular changes consistent with HPV, MILD DYSPLASIA and CIN 1 are combined within the category of LSIL",MILD DYSPLASIA,LSIL
503669168,7/16/2014 21:41:22,,1324494513,7/16/2014 21:39:54,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[TREATS] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]",are combined within,[TREATS] [ASSOCIATED_WITH],38,99,51,103,1,RO-disease_has_finding,901883-FS1,"Cellular changes consistent with HPV, MILD DYSPLASIA and CIN 1 are combined within the category of LSIL",MILD DYSPLASIA,LSIL
503669168,7/16/2014 21:52:12,,1324498843,7/16/2014 21:51:33,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[PART_OF],[PART_OF],Cellular changes consistent with MILD DYSPLASIA are combined within the category of LSIL,N/A,38,99,51,103,1,RO-disease_has_finding,901883-FS1,"Cellular changes consistent with HPV, MILD DYSPLASIA and CIN 1 are combined within the category of LSIL",MILD DYSPLASIA,LSIL
503669168,7/16/2014 21:59:45,,1324501659,7/16/2014 21:59:15,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],changes consistent with and,N/A,38,99,51,103,1,RO-disease_has_finding,901883-FS1,"Cellular changes consistent with HPV, MILD DYSPLASIA and CIN 1 are combined within the category of LSIL",MILD DYSPLASIA,LSIL
503669168,7/16/2014 22:08:46,,1324504758,7/16/2014 22:08:08,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MILD DYSPLASIA are combined LSIL,n/a,38,99,51,103,1,RO-disease_has_finding,901883-FS1,"Cellular changes consistent with HPV, MILD DYSPLASIA and CIN 1 are combined within the category of LSIL",MILD DYSPLASIA,LSIL
503669168,7/16/2014 22:14:20,,1324506741,7/16/2014 22:13:26,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[NONE],[NONE],N/A,N/A,38,99,51,103,1,RO-disease_has_finding,901883-FS1,"Cellular changes consistent with HPV, MILD DYSPLASIA and CIN 1 are combined within the category of LSIL",MILD DYSPLASIA,LSIL
503669168,7/16/2014 22:16:56,,1324507798,7/16/2014 22:16:21,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[PART_OF],[PART_OF],combined within,na,38,99,51,103,1,RO-disease_has_finding,901883-FS1,"Cellular changes consistent with HPV, MILD DYSPLASIA and CIN 1 are combined within the category of LSIL",MILD DYSPLASIA,LSIL
503669168,7/16/2014 23:00:08,,1324525261,7/16/2014 22:59:32,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",are combined within,N/A,38,99,51,103,1,RO-disease_has_finding,901883-FS1,"Cellular changes consistent with HPV, MILD DYSPLASIA and CIN 1 are combined within the category of LSIL",MILD DYSPLASIA,LSIL
503669168,7/16/2014 23:12:59,,1324529871,7/16/2014 23:12:45,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,list,38,99,51,103,1,RO-disease_has_finding,901883-FS1,"Cellular changes consistent with HPV, MILD DYSPLASIA and CIN 1 are combined within the category of LSIL",MILD DYSPLASIA,LSIL
503669168,7/16/2014 23:14:22,,1324530361,7/16/2014 23:13:40,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[PART_OF],[PART_OF],are combined within the category of,N/A,38,99,51,103,1,RO-disease_has_finding,901883-FS1,"Cellular changes consistent with HPV, MILD DYSPLASIA and CIN 1 are combined within the category of LSIL",MILD DYSPLASIA,LSIL
503669169,7/16/2014 21:20:50,,1324486180,7/16/2014 21:20:18,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[IS_A],[IS_A],leg,N/A,57,63,60,71,-1,RO-has_definitional_manifestation,904678-FS1,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
503669169,7/16/2014 21:22:52,,1324487017,7/16/2014 21:22:29,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[SYMPTOM],[SYMPTOM],PAIN (SCIATICA,N/A,57,63,60,71,-1,RO-has_definitional_manifestation,904678-FS1,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
503669169,7/16/2014 21:25:17,,1324488151,7/16/2014 21:25:04,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],PAIN (SCIATICA,N/A,57,63,60,71,-1,RO-has_definitional_manifestation,904678-FS1,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
503669169,7/16/2014 21:25:22,,1324488183,7/16/2014 21:24:56,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],PAIN (SCIATICA,N/A,57,63,60,71,-1,RO-has_definitional_manifestation,904678-FS1,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
503669169,7/16/2014 21:27:22,,1324489100,7/16/2014 21:27:10,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],(SCIATICA,N/A,57,63,60,71,-1,RO-has_definitional_manifestation,904678-FS1,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
503669169,7/16/2014 21:29:27,,1324489994,7/16/2014 21:28:36,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],stay,N/A,57,63,60,71,-1,RO-has_definitional_manifestation,904678-FS1,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
503669169,7/16/2014 21:36:19,,1324492608,7/16/2014 21:36:08,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SYMPTOM],[SYMPTOM],(SCIATICA,N/A,57,63,60,71,-1,RO-has_definitional_manifestation,904678-FS1,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
503669169,7/16/2014 21:36:55,,1324492839,7/16/2014 21:36:41,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[ASSOCIATED_WITH],[ASSOCIATED_WITH],because PAIN,asd,57,63,60,71,-1,RO-has_definitional_manifestation,904678-FS1,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
503669169,7/16/2014 21:43:02,,1324495181,7/16/2014 21:42:51,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[IS_A],[IS_A],PAIN (SCIATICA,N/A,57,63,60,71,-1,RO-has_definitional_manifestation,904678-FS1,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
503669169,7/16/2014 21:44:48,,1324495937,7/16/2014 21:44:01,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[CAUSES],[CAUSES],because of my back or leg,[CAUSES],57,63,60,71,-1,RO-has_definitional_manifestation,904678-FS1,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
503669169,7/16/2014 22:01:24,,1324502244,7/16/2014 22:00:46,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",or PAIN (SCIATICA,n/a,57,63,60,71,-1,RO-has_definitional_manifestation,904678-FS1,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
503669169,7/16/2014 22:05:12,,1324503669,7/16/2014 22:03:23,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[SYMPTOM],[SYMPTOM],PAIN (SCIATICA,Na,57,63,60,71,-1,RO-has_definitional_manifestation,904678-FS1,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
503669169,7/16/2014 22:41:58,,1324518317,7/16/2014 22:41:43,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],or,n/a,57,63,60,71,-1,RO-has_definitional_manifestation,904678-FS1,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
503669169,7/16/2014 22:58:04,,1324524602,7/16/2014 22:57:32,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[IS_A],[IS_A],PAIN (SCIATICA,N/A,57,63,60,71,-1,RO-has_definitional_manifestation,904678-FS1,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
503669169,7/16/2014 22:58:33,,1324524757,7/16/2014 22:57:47,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[NONE],[NONE],N/A,No related terms can be found.,57,63,60,71,-1,RO-has_definitional_manifestation,904678-FS1,I stay in bed most of the time because of my back or leg PAIN (SCIATICA,PAIN,SCIATICA
503669170,7/16/2014 21:19:37,,1324485674,7/16/2014 21:19:21,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[LOCATION],[LOCATION],refers to,N/A,95,116,108,164,1,RO-disease_has_primary_anatomic_site,902415-FS1,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
503669170,7/16/2014 21:23:32,,1324487315,7/16/2014 21:22:40,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",refers to,N/A,95,116,108,164,1,RO-disease_has_primary_anatomic_site,902415-FS1,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
503669170,7/16/2014 21:27:26,,1324489121,7/16/2014 21:27:03,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],CRANIAL NERVE DISORDERS,N/A,95,116,108,164,1,RO-disease_has_primary_anatomic_site,902415-FS1,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
503669170,7/16/2014 21:35:34,,1324492338,7/16/2014 21:35:18,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],(see,N/A,95,116,108,164,1,RO-disease_has_primary_anatomic_site,902415-FS1,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
503669170,7/16/2014 21:37:09,,1324492925,7/16/2014 21:36:58,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[MANIFESTATION],[MANIFESTATION],AND CRANIAL,asd,95,116,108,164,1,RO-disease_has_primary_anatomic_site,902415-FS1,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
503669170,7/16/2014 21:50:26,,1324498127,7/16/2014 21:47:42,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[LOCATION],[LOCATION],refers to the CRANIAL NERVES,n/a,95,116,108,164,1,RO-disease_has_primary_anatomic_site,902415-FS1,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
503669170,7/16/2014 21:58:05,,1324501115,7/16/2014 21:57:07,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[LOCATION],[LOCATION],The peripheral nervous system refers to the CRANIAL NERVES (see NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS,N/A,95,116,108,164,1,RO-disease_has_primary_anatomic_site,902415-FS1,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
503669170,7/16/2014 22:06:59,,1324504192,7/16/2014 22:05:59,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CRANIAL NERVES NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS,n/a,95,116,108,164,1,RO-disease_has_primary_anatomic_site,902415-FS1,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
503669170,7/16/2014 22:17:38,,1324508068,7/16/2014 22:17:00,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[LOCATION],[LOCATION],CRANIAL NERVE,na,95,116,108,164,1,RO-disease_has_primary_anatomic_site,902415-FS1,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
503669170,7/16/2014 22:21:42,,1324509829,7/16/2014 22:21:23,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PERIPHERAL NERVOUS SYSTEM DISORDERS INTRODUCTION refers to the CRANIAL NERVES,N/A,95,116,108,164,1,RO-disease_has_primary_anatomic_site,902415-FS1,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
503669170,7/16/2014 23:03:51,,1324526576,7/16/2014 23:03:01,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",refers to,N/A,95,116,108,164,1,RO-disease_has_primary_anatomic_site,902415-FS1,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
503669170,7/16/2014 23:08:40,,1324528221,7/16/2014 23:08:26,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[LOCATION],[LOCATION],refers to the CRANIAL,N/A,95,116,108,164,1,RO-disease_has_primary_anatomic_site,902415-FS1,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
503669170,7/16/2014 23:20:53,,1324533410,7/16/2014 23:20:08,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[LOCATION],[LOCATION],refers to the,na,95,116,108,164,1,RO-disease_has_primary_anatomic_site,902415-FS1,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
503669170,7/16/2014 23:23:30,,1324534783,7/16/2014 23:22:18,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[LOCATION],[LOCATION],(see,N/A,95,116,108,164,1,RO-disease_has_primary_anatomic_site,902415-FS1,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
503669170,7/16/2014 23:24:19,,1324535243,7/16/2014 23:22:18,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[IS_A],[IS_A],refers to,N/A,95,116,108,164,1,RO-disease_has_primary_anatomic_site,902415-FS1,PERIPHERAL NERVOUS SYSTEM DISORDERS  INTRODUCTION  The peripheral nervous system refers to the CRANIAL NERVES (see  NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS and spinal nerves from their origin to their end.,CRANIAL NERVES,NEURO OPHTHALMOLOGIC AND CRANIAL NERVE DISORDERS
503669171,7/16/2014 21:22:22,,1324486798,7/16/2014 21:22:00,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,47,0,58,27,1,RO-disease_has_finding,901646-FS1,HYPERTENSIVE ENCEPHALOPATHY is associated with HYPERTENSION from any cause and may occur at any age.,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503669171,7/16/2014 21:27:02,,1324488969,7/16/2014 21:26:50,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is associated with,N/A,47,0,58,27,1,RO-disease_has_finding,901646-FS1,HYPERTENSIVE ENCEPHALOPATHY is associated with HYPERTENSION from any cause and may occur at any age.,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503669171,7/16/2014 21:28:10,,1324489394,7/16/2014 21:27:56,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is associated with,N/A,47,0,58,27,1,RO-disease_has_finding,901646-FS1,HYPERTENSIVE ENCEPHALOPATHY is associated with HYPERTENSION from any cause and may occur at any age.,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503669171,7/16/2014 21:35:31,,1324492333,7/16/2014 21:35:17,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SIDE_EFFECT],[SIDE_EFFECT],ENCEPHALOPATHY,asd,47,0,58,27,1,RO-disease_has_finding,901646-FS1,HYPERTENSIVE ENCEPHALOPATHY is associated with HYPERTENSION from any cause and may occur at any age.,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503669171,7/16/2014 21:44:00,,1324495583,7/16/2014 21:43:37,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,[ASSOCIATED_WITH],47,0,58,27,1,RO-disease_has_finding,901646-FS1,HYPERTENSIVE ENCEPHALOPATHY is associated with HYPERTENSION from any cause and may occur at any age.,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503669171,7/16/2014 21:44:32,,1324495805,7/16/2014 21:44:22,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPERTENSIVE ENCEPHALOPATHY is associated with HYPERTENSION,N/A,47,0,58,27,1,RO-disease_has_finding,901646-FS1,HYPERTENSIVE ENCEPHALOPATHY is associated with HYPERTENSION from any cause and may occur at any age.,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503669171,7/16/2014 21:44:45,,1324495885,7/16/2014 21:44:27,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,47,0,58,27,1,RO-disease_has_finding,901646-FS1,HYPERTENSIVE ENCEPHALOPATHY is associated with HYPERTENSION from any cause and may occur at any age.,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503669171,7/16/2014 22:03:04,,1324502928,7/16/2014 22:02:44,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is associated with,N/A,47,0,58,27,1,RO-disease_has_finding,901646-FS1,HYPERTENSIVE ENCEPHALOPATHY is associated with HYPERTENSION from any cause and may occur at any age.,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503669171,7/16/2014 22:05:42,,1324503846,7/16/2014 22:05:13,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is associated with,Na,47,0,58,27,1,RO-disease_has_finding,901646-FS1,HYPERTENSIVE ENCEPHALOPATHY is associated with HYPERTENSION from any cause and may occur at any age.,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503669171,7/16/2014 22:05:58,,1324503903,7/16/2014 22:05:27,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPERTENSIVE ENCEPHALOPATHY is associated with HYPERTENSION,n/a,47,0,58,27,1,RO-disease_has_finding,901646-FS1,HYPERTENSIVE ENCEPHALOPATHY is associated with HYPERTENSION from any cause and may occur at any age.,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503669171,7/16/2014 22:20:47,,1324509497,7/16/2014 22:20:32,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPERTENSIVE ENCEPHALOPATHY is associated with HYPERTENSION,N/A,47,0,58,27,1,RO-disease_has_finding,901646-FS1,HYPERTENSIVE ENCEPHALOPATHY is associated with HYPERTENSION from any cause and may occur at any age.,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503669171,7/16/2014 22:50:05,,1324521241,7/16/2014 22:49:34,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,47,0,58,27,1,RO-disease_has_finding,901646-FS1,HYPERTENSIVE ENCEPHALOPATHY is associated with HYPERTENSION from any cause and may occur at any age.,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503669171,7/16/2014 23:15:43,,1324530873,7/16/2014 23:14:55,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is associated with,N/A,47,0,58,27,1,RO-disease_has_finding,901646-FS1,HYPERTENSIVE ENCEPHALOPATHY is associated with HYPERTENSION from any cause and may occur at any age.,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503669171,7/16/2014 23:15:49,,1324530909,7/16/2014 23:15:39,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,47,0,58,27,1,RO-disease_has_finding,901646-FS1,HYPERTENSIVE ENCEPHALOPATHY is associated with HYPERTENSION from any cause and may occur at any age.,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503669171,7/16/2014 23:22:16,,1324534158,7/16/2014 23:20:23,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,47,0,58,27,1,RO-disease_has_finding,901646-FS1,HYPERTENSIVE ENCEPHALOPATHY is associated with HYPERTENSION from any cause and may occur at any age.,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
503669172,7/16/2014 21:22:28,,1324486840,7/16/2014 21:22:05,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,N/A,308,262,332,271,-1,RO-disease_has_finding,901921-FS1,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of SEBACEOMA 1 case of basal cell carcinoma with SEBACEOUS DIFFERENTIATION and 12 cases of basal cell carcinoma with cytologic atypia.",SEBACEOUS DIFFERENTIATION,SEBACEOMA
503669172,7/16/2014 21:26:02,,1324488502,7/16/2014 21:25:45,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,308,262,332,271,-1,RO-disease_has_finding,901921-FS1,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of SEBACEOMA 1 case of basal cell carcinoma with SEBACEOUS DIFFERENTIATION and 12 cases of basal cell carcinoma with cytologic atypia.",SEBACEOUS DIFFERENTIATION,SEBACEOMA
503669172,7/16/2014 21:26:54,,1324488883,7/16/2014 21:26:18,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[MANIFESTATION],[MANIFESTATION],case of basal cell carcinoma with,N/A,308,262,332,271,-1,RO-disease_has_finding,901921-FS1,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of SEBACEOMA 1 case of basal cell carcinoma with SEBACEOUS DIFFERENTIATION and 12 cases of basal cell carcinoma with cytologic atypia.",SEBACEOUS DIFFERENTIATION,SEBACEOMA
503669172,7/16/2014 21:31:32,,1324490691,7/16/2014 21:31:19,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],SEBACEOUS DIFFERENTIATION,asd,308,262,332,271,-1,RO-disease_has_finding,901921-FS1,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of SEBACEOMA 1 case of basal cell carcinoma with SEBACEOUS DIFFERENTIATION and 12 cases of basal cell carcinoma with cytologic atypia.",SEBACEOUS DIFFERENTIATION,SEBACEOMA
503669172,7/16/2014 21:35:49,,1324492434,7/16/2014 21:35:35,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,308,262,332,271,-1,RO-disease_has_finding,901921-FS1,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of SEBACEOMA 1 case of basal cell carcinoma with SEBACEOUS DIFFERENTIATION and 12 cases of basal cell carcinoma with cytologic atypia.",SEBACEOUS DIFFERENTIATION,SEBACEOMA
503669172,7/16/2014 21:43:00,,1324495164,7/16/2014 21:41:47,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],including,N/A,308,262,332,271,-1,RO-disease_has_finding,901921-FS1,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of SEBACEOMA 1 case of basal cell carcinoma with SEBACEOUS DIFFERENTIATION and 12 cases of basal cell carcinoma with cytologic atypia.",SEBACEOUS DIFFERENTIATION,SEBACEOMA
503669172,7/16/2014 21:43:17,,1324495297,7/16/2014 21:43:03,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[NONE],[NONE],N/A,"Different, unrelated cases",308,262,332,271,-1,RO-disease_has_finding,901921-FS1,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of SEBACEOMA 1 case of basal cell carcinoma with SEBACEOUS DIFFERENTIATION and 12 cases of basal cell carcinoma with cytologic atypia.",SEBACEOUS DIFFERENTIATION,SEBACEOMA
503669172,7/16/2014 21:49:05,,1324497586,7/16/2014 21:47:47,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],excisional specimens obtained SEBACEOMA SEBACEOUS DIFFERENTIATION,n/a,308,262,332,271,-1,RO-disease_has_finding,901921-FS1,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of SEBACEOMA 1 case of basal cell carcinoma with SEBACEOUS DIFFERENTIATION and 12 cases of basal cell carcinoma with cytologic atypia.",SEBACEOUS DIFFERENTIATION,SEBACEOMA
503669172,7/16/2014 21:53:22,,1324499306,7/16/2014 21:52:49,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",cell carcinoma with,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],308,262,332,271,-1,RO-disease_has_finding,901921-FS1,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of SEBACEOMA 1 case of basal cell carcinoma with SEBACEOUS DIFFERENTIATION and 12 cases of basal cell carcinoma with cytologic atypia.",SEBACEOUS DIFFERENTIATION,SEBACEOMA
503669172,7/16/2014 22:00:46,,1324501994,7/16/2014 21:59:54,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],The authors specimens including cases of SEBACEOMA SEBACEOUS DIFFERENTIATION,N/A,308,262,332,271,-1,RO-disease_has_finding,901921-FS1,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of SEBACEOMA 1 case of basal cell carcinoma with SEBACEOUS DIFFERENTIATION and 12 cases of basal cell carcinoma with cytologic atypia.",SEBACEOUS DIFFERENTIATION,SEBACEOMA
503669172,7/16/2014 22:01:59,,1324502455,7/16/2014 22:00:49,clixsense,1.0,15189335,GBR,H9,London,188.29.165.175,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],studied,Na,308,262,332,271,-1,RO-disease_has_finding,901921-FS1,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of SEBACEOMA 1 case of basal cell carcinoma with SEBACEOUS DIFFERENTIATION and 12 cases of basal cell carcinoma with cytologic atypia.",SEBACEOUS DIFFERENTIATION,SEBACEOMA
503669172,7/16/2014 22:10:25,,1324505260,7/16/2014 22:09:32,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],case of with,na,308,262,332,271,-1,RO-disease_has_finding,901921-FS1,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of SEBACEOMA 1 case of basal cell carcinoma with SEBACEOUS DIFFERENTIATION and 12 cases of basal cell carcinoma with cytologic atypia.",SEBACEOUS DIFFERENTIATION,SEBACEOMA
503669172,7/16/2014 22:18:11,,1324508271,7/16/2014 22:17:37,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[NONE],[NONE],N/A,N/A,308,262,332,271,-1,RO-disease_has_finding,901921-FS1,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of SEBACEOMA 1 case of basal cell carcinoma with SEBACEOUS DIFFERENTIATION and 12 cases of basal cell carcinoma with cytologic atypia.",SEBACEOUS DIFFERENTIATION,SEBACEOMA
503669172,7/16/2014 22:28:43,,1324512809,7/16/2014 22:28:14,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],including,n/a,308,262,332,271,-1,RO-disease_has_finding,901921-FS1,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of SEBACEOMA 1 case of basal cell carcinoma with SEBACEOUS DIFFERENTIATION and 12 cases of basal cell carcinoma with cytologic atypia.",SEBACEOUS DIFFERENTIATION,SEBACEOMA
503669172,7/16/2014 22:47:10,,1324520256,7/16/2014 22:46:54,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,308,262,332,271,-1,RO-disease_has_finding,901921-FS1,"The authors studied the immunohistochemical expression of T antigen in 45 skin biopsy and excisional specimens obtained from the archives of their dermatopathology laboratories, including 8 cases of sebaceous carcinoma, 15 cases of sebaceous adenoma, 9 cases of SEBACEOMA 1 case of basal cell carcinoma with SEBACEOUS DIFFERENTIATION and 12 cases of basal cell carcinoma with cytologic atypia.",SEBACEOUS DIFFERENTIATION,SEBACEOMA
